Pharmacological cardioprotection of the human myocardium in diseased states by Rees, P.S.C.
1 
 
Pharmacological cardioprotection of the 
human myocardium in diseased states 
 
Thesis submitted by 
 
Paul S C Rees 
 
MBBS, MRCP(UK), MRCP(London) Dip IMC RCS(Ed) 
 
Surgeon Lieutenant Commander Royal Navy 
 
For the degree of 
 
Doctorate of Medicine, MD(Res) 
 
In the  
 
Faculty of Medicine,  
 
UCL 
 
 
The Hatter Cardiovascular Institute 
 
67, Chenies Mews, London WC1E 6HX 
 
2011
2 
 
Declaration 
I, Paul Stuart Chadwick Rees, confirm that the work presented in this thesis 
is my own.  Where information has been derived from other sources, I 
confirm that this has been indicated in the thesis. 
 
 
 
Paul Stuart Chadwick Rees 
 
3 
 
ABSTRACT 
BACKGROUND 
Coronary artery disease is the leading worldwide cause of death.  Even 
despite restoration of blood flow following acute myocardial infarction, further 
myocardial damage is seen during the reperfusion phase.  Pharmacological 
strategies to induce resistance to ischaemia reperfusion injury have been 
shown to share common pathways.  The most important common signalling 
pathway involved is the Reperfusion Injury Salvage Kinase pathway, and in 
animal models this can be pharmacologically activated, resulting in inhibition 
of the opening of the mitochondrial permeability transition pore, with a 
resultant cardioprotective effect.  Atorvastatin has been shown to act in this 
way in animal models of ischaemia-reperfusion injury, although this has not 
been demonstrated in humans.  This thesis examines (a) the role of 
atorvastatin in acute protection from ischaemia-reperfusion injury in human 
myocardium, (b) the ability of high-dose atorvastatin to recapture 
cardioprotection in human myocardium in the setting of chronic statin 
therapy, and (c) the functionality of the mitochondrial permeability transition 
pore in human hypertrophic cardiomyopathy, and the role of atorvastatin in 
inhibiting pore opening following oxidative stress. 
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METHODS AND RESULTS 
Using human models to simulate ischaemia-reperfusion injury we have 
demonstrated: (1) Human atrial myocardium can be protected from 
simulated ischaemia-reperfusion injury by treatment with atorvastatin at the 
time of reperfusion; (2) Cardioprotection against simulated ischaemia-
reperfusion injury can be recaptured with high-dose atorvastatin; (3) The 
mitochondrial permeability transition pore is a critical determinant in cell 
death in hypertrophic cardiomyopathy, and its inhibition can be achieved 
using atorvastatin. 
CONCLUSION 
The key aim of emergency reperfusion therapy in the setting of myocardial 
infarction is salvage of myocardium and preservation of cardiac function.  
These studies contribute to the field by exploring the cardioprotective effects 
of atorvastatin in human myocardium and delineating protective cascades 
involved.  They offer a key translational step in our understanding of statin 
cardioprotection, and an insight into cardioprotection in hypertrophic 
cardiomyopathy.
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Chapter One:  INTRODUCTION 
Coronary Artery Disease – The Leading Killer  
Despite major advances in its prevention and treatment, coronary artery 
disease (CAD) remains the leading worldwide cause of death, killing around 
8 million people annually. In the UK, 1 in 5 men, and 1 in 7 women will die 
from this disease (1).   In low and middle income countries in 2001, CAD 
accounted for 11.8% of all deaths, rising to 17.3% in more affluent states (2). 
World Health Organisation predictions suggest that this trend will continue to 
accelerate well into this century, with CAD becoming the leading cause of 
both death and disability by 2020 (3), owing to a rapid increase in prevalence 
in developing countries, eastern Europe and the rising incidence of obesity 
and diabetes. 
 
Pathophysiology 
Following the development of an accumulation of lipid-laden cells beneath 
the vascular endothelium – a fatty streak – atherosclerotic lesions develop 
(4).  These are asymmetric focal thickenings of the intima, the innermost 
arterial layer.  With progression, these lesions may become obstructive to 
coronary blood flow, resulting in myocardial ischaemia under conditions of 
demand.  This leads to the clinical presentation of exertional angina. The 
condition is treated by aggressive medical therapy with anti-anginal and 
secondary prevention medications (5), and revascularisation by means of 
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percutaneous coronary intervention (PCI) or coronary artery bypass grafting 
(6).   
The most dramatic presentation of CAD is that of myocardial infarction.  In 
this process, activation of an atheromatous plaque leads to thrombus 
formation on its surface, leading to vessel occlusion.  The actions of a 
cascade of inflammatory cytokines, proteases, coagulation factors, free 
radicals and vasoactive substances combine at the culprit lesion in the 
coronary tree (7).  Their combined actions destabilise the coronary lesion by 
attacking collagen within, leading to rupture of its fibrous cap. This may 
occur even in the absence of angiographically severe coronary stenosis (8). 
Plaque rupture, detectable in 70% of cases, exposes pro-thrombotic material 
from the plaque core to the blood, and this triggers acute thrombus formation 
(9).  Thrombus propagation leads to total coronary occlusion, and 
downstream ischaemia then follows.  Untreated this will lead to myocardial 
infarction, with the development of myocardial scar, and impairment of left 
ventricular function.  The most important determinant of future prognosis is 
infarct size (10-12), and experimental animal studies in the 1970s sought to 
address this. 
 
Emergency Reperfusion Therapy 
 
The most effective strategy for salvaging myocardium in the setting of acute 
myocardial infarction due to occlusive thrombus is prompt reperfusion 
therapy (13-15).  This life-saving therapy is now best delivered through an 
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organised primary PCI network (16) combining direct transport to a PCI 
centre, optimal antiplatelet (17) and antithrombin treatments (18), followed 
by emergency PCI with thrombus aspiration (19) to re-open the vessel.  This 
will result in reperfusion of the vessel in over 95% of cases.  If unavailable, 
thrombolytic therapy to dissolve the occlusive thrombus remains an option, 
though with less efficacy and more side effects (20-23).  Emergency 
reperfusion therapy has been shown to save life, reduce recurrent 
myocardial events and preserve left ventricular function and should be 
offered even when cardiac arrest ensues (24;25) 
 
Myocardial Reperfusion Leads to Further Cell Death – 
Reperfusion Injury 
 
Despite prompt reperfusion, some cardiomyocytes in the culprit territory will 
go on to die.  In 1960, Jennings et al first described a host of adverse 
histological findings found in myocardium which had been reperfused 
following temporary coronary artery occlusion in a canine model (26).  This 
phenomenon of myocardial reperfusion injury may account for up to 50% of 
the final infarct size (27).  A number of different contributory factors have 
been postulated, and form the basis for attempts to develop therapies with 
which to combat myocardial reperfusion injury (28;29) .   
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Oxidative Stress and Reactive Oxygen Species Generation 
 
A large burst of oxidative stress is generated following reperfusion of 
ischaemic myocardium.  In 1988, Zweier demonstrated a direct relationship 
between free radical generation and subsequent impaired myocardial 
contractile function.  The study confirmed that reactive oxygen species 
(ROS) are generated in the reperfused myocardium, and that these radicals 
appear to be key mediators of myocardial reperfusion injury (30;31).  The 
increase in ROS is thought to be due to damage to electron transport chain 
components, leading to inefficient transfer of electrons and generation of 
superoxides (32).  Additionally, oxidative stress during reperfusion leads to 
depletion of nitric oxide (NO), an agent known to possess cardioprotective 
effects through its ability to regulate coronary flow, inactivate superoxide 
forms and inhibit neutrophil chemotaxis to the injured site (33). Thus, the at-
risk myocardium in the jeopardised territory is further deprived of the 
potential benefits of an in-house cardioprotective agent.  
 
pH flux and calcium accumulation 
 
Following reperfusion, the pH is rapidly restored to within normal 
physiological limits.  Paradoxically, this rapid correction in pH following 
reperfusion has been shown to contribute to lethal reperfusion injury (34). pH 
changes are also implicated in inducing adverse changes in calcium 
handling.  During reperfusion, following the restoration of normal 
extracellular pH, intracellular calcium levels transiently rise as hydrogen and 
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sodium ions are extruded from the cell by ion exchange pumps.  A 
sodium/calcium exchange pump, triggered by elevated intracellular sodium, 
actively imports calcium into the cell. Subsequent oscillations in intracellular 
calcium can lead to hypercontracture of the myocytes, depleting myocyte 
ATP levels and causing them to deteriorate.  In some cells intracellular 
calcium levels remain high even after immediate reperfusion, and these cells 
are typically irreversibly damaged (32).  Direct damage to the sarcoplasmic 
reticulum and sarcolemnal membrane also contribute, overwhelming the 
cell‟s ability to regulate calcium, leading to cell and mitochondrial calcium 
overload (35). 
 
Cell Death - Necrosis, Apoptosis and Autophagy 
 
The myocardial cellular injury sustained during ischaemia-reperfusion injury 
is believed to be due to a combination of necrosis, apoptosis and autophagy 
(32;36;37).  Necrosis is an irreversible and non-regulated process of cell 
death associated with prolonged periods of ischaemia, whereas apoptosis 
and autophagy are programmed events which involve the activation of 
complex signalling pathways (38).   
Apoptosis is an energy-requiring process that follows a defined time-
sensitive signalling pathway.  It leads to cell shrinkage, plasma membrane 
changes, intracellular proteolysis, loss of mitochondrial function and DNA 
fragmentation (39).  Its immediate objective is the safe dismantling of 
intracellular components and two central pathways are involved in triggering 
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the process.  An “extrinsic” pathway involves activation of cell surface death 
receptors by binding of ligands to tumour necrosis factor family receptors 
(40).  A second “intrinsic” pathway is activated by apoptotic signals inside the 
cell which involve mitochondria as either initiators or signal magnifiers (41).  
Loss of ventricular myocytes by apoptosis has been heavily implicated in 
ischaemia-reperfusion injury (42), with apoptotic cascades being enhanced 
during the reperfusion phase as substrate levels and subsequent metabolic 
processes are restored (43;44), and post-ischaemic salvage strategies are 
aimed at reducing this myocyte loss with its concomitant potential for 
deterioration in ventricular contractile function (45). 
Autophagy is a highly orchestrated cellular catabolic process by which 
proteins and organelles are degraded to generate free amino acids and 
sugars during periods of metabolic stress (46).  Autophagy in mammalian 
cells occurs via three main pathways, the commonest being 
macroautophagy which will be discussed further (47).  In cardiomyocytes, 
autophagy is seen under normal physiological conditions and represents a 
housekeeping function, removing damaged proteins and macro-molecular 
structures.  During periods of cellular stress, autophagy is rapidly induced, 
possibly as a survival mechanism initially, eventually leading to cell death 
when repair of the injured cardiomyocyte is impossible (48).  Studies have 
shown that autophagy is upregulated during myocardial ischaemia-
reperfusion injury (49), and in these conditions many of the autophagosomes 
contain (presumably damaged) mitochondria (50).  The exact role of 
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autophagy within the heart is not fully understood, and its regulation is not 
fully delineated.  Work in this field remains ongoing.  However it seems likely 
that cross-talk exists between autophagy and apoptosis as means of cell 
death, and this probably involves the mitochondrion as a common point in 
both pathways (46). 
 
The Mitochondrial Permeability Transition Pore 
 
The onset of reperfusion has been shown to activate a nonselective channel 
of the internal mitochondrial membrane, termed the mitochondrial 
permeability transition pore (mPTP) (27;51-53). This is a large-conductance 
megachannel comprising a voltage-dependent anion channel in the outer 
mitochondrial membrane, the adenine nucleotide transporter on the inner 
membrane, and cyclophilin D in the matrix (54). Induced in the first few 
minutes following reperfusion, triggered by mitochondrial calcium excess, 
oxidative stress, electron transport chain abnormalities and ATP depletion 
(31;55), the pore is a critical determinant of cell death (56).  Studies in 1988 
first confirmed the involvement of the mPTP in reperfusion injury by 
demonstrating its sensitivity to intracellular calcium levels and oxidative 
stress, all conditions present during reperfusion (57).    
 
mPTP opening triggers apoptosis 
 
Formation and opening of the mPTP results in depolarisation of the inner 
mitochondrial membrane potential and matrix swelling.  Mitochondrial 
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swelling, in turn,  leads to rupture of the outer mitochondrial membrane with 
subsequent release of pro-apoptotic factors such as cytochrome c and 
apoptosis-inducing-factor into the cytosol (58).  These go on to activate 
caspase cascades involving caspase-9 (59).  Caspase activation is 
detectable within 30 minutes of the onset of ischaemia, with DNA 
fragmentation seen after 60 minutes.  Both features accelerate during the 
reperfusion phase, and inhibition of this process has been shown to reduce 
apoptosis in experimental models (60;61). Unchecked, the downstream 
effect is cellular fragmentiation and eventual cell death.  mPTP opening is 
also believed to have a role in triggering autophagy, which could possibly act 
as a myocyte-rescue mechanism, saving myocytes from apoptotic death 
(46). 
 
Inhibition of the mPTP is cardioprotective 
 
 Crompton‟s group demonstrated that pharmacological inhibition of the pore 
could be induced by the administration of cyclosporin A, which inhibits the 
enzymatic action of cyclophilin D within the pore (62),  . Later this agent was 
used to successfully improve cell survival following anoxia in adult rat 
cardiomyocytes (63).  Studies in human atrial myocytes by our research 
group have confirmed that the mPTP is a target for cardioprotection in 
humans, and that its direct pharmacological inhibition can be used to 
lengthen individual cell survival when exposed to oxidative stress, as well as 
improve contractile function after hypoxia-reoxygenation injury (64) .  
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Inhibition of the pore can be also achieved by activation of prosurvival 
signalling cascades which will be discussed in more depth later in this 
chapter (65).  Targeting this pore has become a key focus of experimental 
and clinical studies attempting designed to optimise outcome from 
myocardial infarction by limiting lethal myocardial reperfusion injury.  
 
Limiting ischaemia-reperfusion injury by preconditioning 
 
Having observed that the rate of myocardial ATP depletion was reduced in 
hearts exposed to brief periods of ischaemia prior to experimental infarction, 
Murry‟s group used a canine model to further test this concept.  
Hypothesizing that brief periods of ischaemia applied up-stream to an 
experimental myocardial infarction might reduce infarct size, they exposed a 
control group to a 40 minute ischaemia-reperfusion injury protocol by 
occluding the circumflex artery, then reperfusing the territory at the end of 
the experiment.  A second group of dogs was exposed to a “preconditioning” 
stimulus comprising four 5 minute occlusions of the circumflex, followed by 
reperfusion, immediately prior to the main 40 minute occlusion.  They noted 
that electrocardiographic changes of ischaemia and infarction were slower to 
develop and less marked in the preconditioned group.   Subsequent 
histological analysis confirmed  a 25% reduction in final infarct size, despite 
a similar amount of myocardium being at risk (66).  The concept of 
ischaemic preconditioning was thus proven, and the phenomenon has 
subsequently been demonstrated in a range of mammalian hearts, including 
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in humans.  Interestingly, protection of the heart is not limited to the coronary 
territory exposed to the preconditioning stimulus, but has a pan-myocardial 
protective effect, with protection seen in areas remote from the 
preconditioned territory (67).  These are indeed key findings, but of limited 
clinical applicability in the setting of acute coronary syndromes, which are 
effectively random unpredictable clinical events.  To be of any clinical 
benefit, a cardioprotective strategy would need to be applied either 
immediately prior to, alongside or after reperfusion.   
However, delineating the mechanisms by which these techniques might 
protect the myocardium remains important, as it may offer trigger 
mechanisms that could be exploited in clinical practice.  In 2002, Yellon‟s 
group first published the importance of the reperfusion injury salvage kinase 
(RISK) pathway.  They demonstrated the importance of this group of pro-
survival kinases which, under specific pharmacological conditions, could be 
activated at reperfusion to the benefit of the myocardium at risk (68).  In 
2005, using an isolated perfused rat heart model of ischaemic 
preconditioning, they went on to assay the phosphorylation states of the 
protein kinase Akt and extracellular signalling kinasesErk1/2.  They found 
that preconditioning also resulted in a transient increase in enzyme 
phosphorylation following the trigger stimulus, but also a four-fold increase at 
the point of reperfusion, associated with an expected decrease in final infarct 
size.  Inhibiting these enzymes abrogated protection, demonstrating their key 
role in cardioprotection.  They confirmed that preconditioning targets the 
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reperfusion phase, and activates the prosurvival kinase RISK cascade (69).  
Being able to activate this pathway acutely during the perfusion phase might 
allow cardioprotection to be applied during acute coronary syndromes.  
Pharmacological activation of the RISK pathway has been shown to induce 
cardioprotection by phosphorylation of a variety of downstream effectors 
including p70S6K (70), Bcl-2-associated death protein promoter (BAD) (70), 
GSK3β  (71) and endothelial nitric oxide synthase (eNOS) (72;73).  Also 
downstream of RISK activation is the mammalian target of rapamycin 
(mTOR), a serine-threonine kinase that regulates protein synthesis and cell 
growth.  Interestingly, mTOR activation is linked to regulation of authophagy 
(46). 
 
Postconditioning 
 
In 2003, Zhao tested the hypothesis that repetitive ischemia applied during 
early reperfusion is cardioprotective by attenuating reperfusion injury. Using 
an anaesthetised, open-chest canine model of left anterior descending (LAD) 
artery occlusion for 3 hours, they applied a preconditioning protocol to one 
group, another group acted as a control, and the study group underwent 3 
cycles of 30 seconds reperfusion followed by 30 seconds re-occlusion of the 
LAD at the onset of reperfusion.  They showed that infarct size was 
significantly less in the preconditioning (15±2%, p<0.05) and 
postconditioning (14±2%, p<0.05) groups compared with controls (25±3%). 
Tissue oedema, leucocyte accumulation, and endothelial function were also 
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more favourable in the postconditioned groups.  These data suggested that 
postconditioning could be as effective as preconditioning in reducing infarct 
size and preserving endothelial function. The authors then went on to 
suggest that postconditioning could potentially be applied in the setting of 
coronary interventions, coronary artery bypass surgery, organ 
transplantation, and peripheral revascularization where reperfusion injury is 
expressed (74).  In subsequent studies they went on to confirm that part of 
the benefit may be derived from an anti-apoptotic effect (75) 
 
In the light of this growing experimental evidence, retrospective data were 
published by Darling et al, assessing biomarker release in cases where 
multiple balloon inflation had been performed during primary PCI.  In cases 
where ≥4 balloon inflations were performed, peak CK levels were lower 
(1655 versus 2272 IU/L; p < 0.05), consistent with the concept that relief of 
sustained ischemia in a stuttered manner (analogous to postconditioning) 
may evoke cardioprotection in the clinical setting  (76) 
 
Postconditioning activates the RISK pathway 
 
To better delineate the signalling mechanisms involved, in 2004 Yellon‟s 
group  performed a postconditioning study using isolated perfused rat hearts.  
They confirmed that postconditioning reduced infarct size from 51.2±3.4% to 
31.5±4.1% (p < 0.01), and that  inhibiting phosphatidylinositol 3-kinase 
(PI3K) at reperfusion using the agents LY294002 or Wortmannin during the 
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first 15 minutes of reperfusion completely abolished postconditioning-
induced protection. Western blot immunochemical analysis demonstrated 
that postconditioning induced a significant increase in phosphorylation of Akt 
and endothelial nitric oxide synthase (eNOS). These findings strongly 
support the suggestion that the effects of postconditioning are mediated by 
activation of the prosurvival kinases PI3K, Akt and eNOS, key components 
of the RISK pathway (77).   
 
In 2005, Staat and colleagues performed a prospective, randomized, 
controlled, multicenter study, to establish whether postconditioning could 
protect the human heart in the setting of primary PCI for acute myocardial 
infarction.  Randomising 30 patients with acutely occluded major coronary 
arteries presenting within 6 hours after the onset of chest pain, the control 
group underwent standard PCI with direct stenting.  The postconditioning 
group underwent 4 episodes of re-inflation of the angioplasty balloon for 1 
minute, followed by restoration of flow for a further minute.  First of all, no 
adverse events were noted as a result of applying the postconditioning 
protocol suggesting the technique can be safely applied.  Analysis of the 
area of myocardium at risk was comparable between the groups.  Total 
creatine kinase release assessed by serial measurements over the next 72 
hours, used as a marker of infarct size, was 36% less in the postconditioned 
group.  Myocardial blush grade - a marker of myocardial reperfusion – was 
also improved in the postconditioned group.  This is interesting as current 
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PCI practice is to avoid repeated balloon inflation during primary PCI due to 
concerns that it might induce the “no-reflow” phenomenon and inhibit 
downstream perfusion of the myocardial capillary bed.  These results 
suggest that might be far from the case.  Overall, this small pilot study 
suggested that postconditioning during primary PCI is safe, feasible and 
protects the human heart during acute myocardial infarction (78).  Longer 
term follow-up data on 38 patients subjected to postconditioning have been 
published, combining nuclear imaging and echocardiography techniques.  
The data confirm improvements in infarct size using single positron emission 
computed tomography (SPECT) at 6 months, and improved overall left 
ventricular function using echocardiography at 1 year, with a statistically (and 
clinically) significant 7% improvement in ejection fraction, confirming that 
postconditioning confers long-term benefits (79). 
 
In a study of 41 patients undergoing primary PCI within 90 minutes of 
admission to hospital, Zhao‟s group published further data in 2007.  Using 
three 30 second balloon re-inflations/deflation cycles during the reperfusion 
phase, infarct size represented by creatine-kinase activity during the first 72 
hours of reperfusion was reduced by 27%.  At 7 days post-PCI, SPECT 
revealed that this translated into a reduced final infarct size (31.3±8.6% vs. 
22.8±6.7% of left ventricle, p<0.05) (80).  
 
29 
 
A recent systematic review and meta-analysis of the six relevant published 
studies in this field confirms a highly-significant (p=0.005) benefit in terms of 
reduction of CK release associated with postconditioning.  Perhaps more 
clinically important still, analysis of the echocardiographic left ventricular 
function ejection fraction shows a highly significant improvement of 4.2% 
where postconditioning is applied, though long-term outcome data have yet 
to be evaluated (81).  Technically, postconditioning with repeated balloon 
inflation is counterintuitive to most interventional cardiologists.  The 
overwhelming drive during a primary PCI is to reopen the occluded vessel 
with as little balloon inflation as possible, for fear of dislodging thrombus 
downstream and injuring the microvasculature.  Despite having evidence to 
support it (albeit from small studies), postconditioning has had, as yet, little 
clinical impact. 
 
Activation of the RISK pathway by postconditioning protects 
human myocardium 
 
Recent studies by our group, using an isolated human atrial trabecular 
model of hypoxia-reoxygenation injury recently delineated the underlying 
cardioprotective cascades in the setting of ischaemic postconditioning.  Right 
atrial samples were taken from 30 consenting patients undergoing elective 
CABG, during the establishment of cardiopulmonary bypass.  Sivaraman et 
al exposed isolated atrial trabeculae to a standard hypoxia re-oxygenation 
protocol, and compared a control group with groups exposed to an 
ischaemic preconditioning protocol and a postconditioned group.  In this 
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group, following a 90 minute hypoxia episode, either four 30 or 60 second 
episodes of alternating hypoxia-reoxygenation were applied at the onset of 
reoxygenation.  Recovery of baseline contractile function was 26.7±2.1% in 
the control group, but 45.2±2.2% in the group given the 60 second cycles of 
postconditioning.  This compared favourably with the improvement in 
function seen in the preconditioned group (45.4±3.2%).  These studies 
demonstrated, for the first time, that postconditioning protects the human 
myocardium ex-vivo (82).  Importantly, administration of LY294002 (a PI3-
kinase inhibitor) and UO126 (an Erk-1/2 inhibitor) abolished the 
cardioprotective effect afforded by postconditioning.  This confirmed that the 
effect was related to activation of prosurvival RISK signalling pathway, 
already well-established as a key mediator of cardioprotection in human 
tissue (83) and animal models (84).   
 
Clinical cardioprotection with statins 
 
3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitors 
(statins) have a well-proven and established role in the management of 
cardiovascular disease (85;86).  As primary prevention agents, they can be 
used to reduce serum levels of low density lipoprotein cholesterol, and 
prevent the development of coronary heart disease (87), and can reduce 
event rates even where cholesterol levels are considered normal (88;89).  
Used as secondary prevention in patients with established coronary disease, 
they significantly reduce further rates of death and recurrent myocardial 
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infarction (90) .  In addition, they have been shown to be able to reduce the 
progression of atherosclerosis, and intravascular ultrasound studies have 
shown evidence of regression of markers of coronary disease burden with 
very intensive statin treatment (91;92). 
  
More recently, attention has turned to the beneficial effects of statins in the 
setting of acute coronary syndromes (ACS).  In the Myocardial Ischaemia 
Reduction with Aggressive Cholesterol Lowering (MIRACL) study, the effect 
of early administration of atorvastatin 80mg following ACS was examined 
against placebo.  With over 3000 patients randomised, the results showed 
reduced readmission for ischaemia at 4 months (93).  Further positive data 
were yielded by a report from the first Euro Heart Study, which showed a 
2.2% absolute mortality reduction at 7 days where statin therapy was 
initiated early in the setting of ST-elevation myocardial infarction.  The same 
didn‟t hold for the non-ST elevation myocardial group, but the concept that 
very early statin therapy might modulate the infarction process is supported 
by these findings (94).   Intensive lipid lowering using atorvastatin 80mg, 
compared alongside pravastatin 40mg was also shown to be beneficial 
following acute ACS, in the Pravastatin or Atorvastatin Evaluation and 
Infection Therapy – Thrombolysis in Myocardial Infarction 22 (PROVE-IT-
TIMI 22) trial (95).  4162 patients were randomized within 10 days of 
presentation with ACS. At the 2 year point, the atorvastatin group had 
demonstrated a reduction in the composite endpoint (of death, myocardial 
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infarction, ACS, coronary revascularisation and stroke) of 16% (95% CI 5-
26%, p=0.005).  Rather than being lipid-dependent, it was suggested that 
some of these differences may be due to other “pleiotropic” effects of statins.  
Alternative mechanisms whereby statin therapy alters the course of ACS are 
thought to include anti-inflammatory effects (88), immune modulation, 
improvement of endothelial function,  inhibition of coagulation ,stabilisation of 
unstable coronary atherosclerotic plaques and reduced adhesion molecule 
expression. (96-98).   
Outside the setting of ACS, the process of PCI itself  can sometimes lead to 
myocyte necrosis, especially where the procedure is technically difficult, 
where coronary anatomy is challenging or where the patients has not been 
exposed to extensive medical pre-treatment, especially where antiplatelet 
loading has been suboptimal (99).   As well as biomarker release, this 
damage has been documented using magnetic resonance imaging (MRI) 
techniques, and where present, is linked to worsened clinical outcomes.  In 
an attempt to investigate whether it was possible to pharmacologically 
influence this, Pasceri et al conducted the Atorvastatin for the Reduction of 
MYocardial Damage During Angioplasty (ARMYDA) study.  This was a 
prospective, randomized study in statin-naïve patients undergoing elective 
PCI.  Randomising patients to either atorvastatin 40mg/day or placebo, they 
demonstrated a striking reduction in periprocedural MI from 18% to 5% in the 
atorvastatin arm (p=0.025) (100).  Further work by the same group in the 
setting of ACS was undertaken in the ARMYDA-ACS study, randomizing 171 
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patients with ACS to atorvastatin 80 mg 12 h before PCl, with a further 40-
mg pre-procedure dose (n = 86) or placebo (n = 85) followed by long-term 
atorvastatin treatment thereafter (40 mg/day) (101). The primary end point 
(death, MI, emergency revascularization) occurred in 5% of patients in the 
atorvastatin arm and in 17% of those in the placebo arm (p=0.01), mostly 
driven by reduction of myocardial infarction incidence (5% vs. 15%, p=0.04). 
Post procedural elevation of creatine kinase-MB and troponin-I was also 
significantly lower in the atorvastatin group (7% vs. 27%, p=0.001 and 41% 
vs. 58%, p=0.039, respectively). Following multivariable analysis, 
pretreatment with atorvastatin conferred an 88% risk reduction of 30 day 
major adverse cardiac events (odds ratio 0.12, 95% confidence interval 0.05 
to 0.50; p=0.004). The short pre-treatment time (12 hours prior to PCI) 
clearly indicates that these effects are independent of lipid-lowering, as this 
takes weeks to achieve, and points more strongly towards one of the 
pleiotropic effects outlined above, or a direct effect on ischaemia-reperfusion 
injury associated with either the index ACS event or the PCI.  A later meta-
analysis of studies of statin use in the setting of PCI confirmed a significant 
reduction in myocardial infarction from 5.2% to 3.0% (odds ratio  0.57, 95% 
confidence interval  0.42 to 0.78, p<0.0001) (102). 
 
Evidence that statins reduce acute ischaemia-reperfusion injury 
 
As far back as 1998, Laufs et al confirmed one of the pleiotropic effects 
which probably plays a key role in the ability of stains to confer 
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cardioprotection.  Using human endothelial cells they demonstrated that 
simvastatin and lovastatin unregulated eNOS expression almost four-fold, 
and confirmed that it was likely that the beneficial effects of statins seen in 
atherosclerosis were more than a product of lipid-lowering. 
An early example of statin cardioprotection was a provided by Lefer et al in 
1999.  They demonstrated that simvastatin preserved contractile function 
and coronary flow in isolated perfused rat hearts exposed to ischaemia-
reperfusion injury.  They attributed this to inhibition of neutrophil mediated 
cardiac dysfunction, and possibly enhanced eNOS release, rather than the 
more direct role in inhibiting ischaemia-reperfusion injury that now seems 
more likely. 
 
Bell, working at our laboratory in 2003, confirmed that atorvastatin has a 
cardioprotective effect when administered at reperfusion.  Using isolated 
perfused mouse hearts subjected to 35 minutes of ischaemia followed by 30 
minutes of reperfusion he demonstrated that atorvastatin caused a marked 
dose-dependent reduction in infarct size.  Optimal cardioprotection was 
achieved at a dose of 50 µM/L, resulting in a final infarct size of 16±2% in the 
atorvastatin group versus 33±2% in the control arm, p<0.01. This protection 
was lost with inhibition of PI3 kinase, and was absent in eNOS knockout 
mice. Western blot analysis revealed that atorvastatin resulted in activation 
of the PI3-K/Akt signaling cascade in the first 5 minutes of reperfusion and 
that both Akt and eNOS phosphorylation were significantly increased.   
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Phosphorylation was also lost in the presence of the PI3-K inhibitor.  The key 
finding was that atorvastatin not only attenuates lethal reperfusion-induced 
injury, but also that the protection afforded is reliant on PI3K and Akt activity 
and the presence and activity of eNOS.  Further work by Birnbaum‟s group 
in Texas has confirmed this finding (103;104), and has sought ways in which 
to pharmacologically enhance the protection by combining atorvastatin with 
agents which further activate eNOS and or inducible NOS (iNOS) such as 
phosphodiesterase inhibitors sildenafil (105) and cilostazol (106;107).  
Synergistic effects were also found with co-administration of atorvastatin with 
dipyridamole, an adenosine reuptake inhibitor, as adenosine also has a role 
in activating eNOS, and triggering cardioprotective mechanisms (108). 
Activation of the RISK pathway by statins has also been confirmed in a 
porcine model of myocardial infarction by Vilahur and colleagues, using 
pretreatment for 7 days with high-dose rosuvastatin.  They confirmed a 
cardioprotective effect, with a significant 7% absolute decrease in infarct 
size, and a 12% improvement in ventricular function, independent of plasma 
lipid levels.  There was elevated protein expression of the RISK kinases Akt 
and Erk-1/2 in the myocardial border zone (109). 
 
The Role of PI3-Kinase in Pharmacological Cardioprotection 
 
Central to pharmacological activation of the prosurvival, antiapoptotic RISK 
pathway lies activation of effectors by phopshatidylinositol 3-kinase (PI3-K) 
(71).  Rather than being a single entity, PI3-K is a family of conserved lipid 
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and protein kinase enzymes which are widely expressed in cells throughout 
the body, including in the myocardium.  As a group, they modulate cell 
survival, hypertrophy, contractility and metabolism.  Importantly, in cardiac 
tissue, PI3-K is responsible for the phosphorylation of phosphatidylinositol 
4,5-bisphosphonate to form phosphatidylinositol 3,4,5-triphosphate 
(PtdIns(3,4,5)P3), an action reversed by PTEN.  PI3-Ks are divided into three 
main classes according to their substrate specificity, though a huge range of 
catalytic and accessory subunit variation is seen (110).  Regarding the heart, 
the Class IA variants PI3K α, β and δ, and the PI3K Class IB γ predominate 
(111).  PI3-K activation enhances cardiomyocyte survival and antagonises 
apoptosis (112).  A recent murine study confirms that PI3-Kγ plays a key role 
in both myocardial ischaemic preconditioning and pharmacological-mediated 
cardioprotection (113).  One central role of PI3-K  in cardioprotection is the 
activation of Akt isoforms, as part of the RISK signalling cascade (114).  
Other downstream targets include glycogen synthase kinase-3 and mTOR 
(112).  
  
 
Human data supporting a direct cardioprotective effect of statins 
 
Human experimental studies which adequately explain the findings of the 
large clinical studies of statin use have been scant.  Using a cellular model of 
hypoxia-reoxygenation injury, Verma provided positive evidence of these 
cardioprotective effects extending to human myocytes.  Using cells 
harvested from the right ventricular outflow tracts of patients undergoing 
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surgery to correct congenital heart disease, his group used 90 minute 
hypoxia/ 30 minute reoxygenation cycles.  Pravastatin treatment directly 
prevented cardiomyocyte death, independent of endothelial or other cell 
types.  In keeping with all the animal data outlined above, this effect was 
mediated by both an increase in NO release and an increase in protein 
kinase Akt activation.   
 
Atorvastatin in clinical context 
Atorvastatin is the most widely used HMG-CoA reductase inhibitor, and is 
safe and well tolerated, even at the intensive therapy dose of 80mg daily 
(115).  Developed during the mid 1990s, atorvastatin is more potent than 
other similar agents with the exception of rosuvastatin.  In terms of lipid 
modulation, 14 days therapy with 80mg daily will result in a 58% reduction in 
LDL-cholesterol.  Based on work in healthy volunteers, at the 80mg dose it 
achieves its maximum observed plasma concentration (252 ng/ml) 2 hours 
after ingestion (116).  This rapid bioavailability lends itself well to use in the 
emergency setting, and if given during the prehospital phase, it is likely that 
a clinically active serum level would be present by the time primary PCI is 
performed, given that current targets aim for a balloon inflation time of less 
than 90 minutes from first medical contact (20). 
Summary and basis for experimental studies 
 
Whilst shown to be protective in most animal and cellular experimental 
models, the ability of atorvastatin to directly protect the human myocardium 
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against ischaemia-reperfusion injury has not been established, and this will 
form the basis for the experimental studies outlined below.  Additionally, it is 
planned to examine whether, when administered at the onset of reperfusion, 
prosurvival signalling pathways including the RISK enzymes PI3K, Erk-1/2, 
and NOS isoforms can be activated with this agent.
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Cardioprotection during revascularisation procedures 
Surgical revascularisation  
 
Cardiac surgery in the United Kingdom is performed for two main indications.  
The most common requirement is as part of a strategy of revascularisation 
for patients suffering from coronary artery disease, termed coronary artery 
bypass grafting (CABG). First performed in the USA in 1967,  this rapidly 
became established as the standard of care for patients suffering from 
symptomatic coronary artery disease (117).  During this procedure, vascular 
conduits are used to bypass blocked or severely stenosed epicardial blood 
vessels, with the aims of improving patient survival, reducing the symptoms 
of angina, and preserving function of the left ventricle.  The conduits used 
are most commonly the left internal mammary artery onto the left anterior 
descending artery, and saphenous vein grafts harvested from the leg, onto 
the circumflex and right coronary artery territories  Even with marked 
advances in minimally invasive percutaneous coronary techniques, CABG 
holds its place as the treatment of choice for some patient groups (6).  
Around 23,000 CABG procedures are performed annually in the UK (118). 
 
Treatment of cardiac valvular disease is the next largest group undergoing 
cardiac surgery.  Degenerative disease affecting the aortic valve is the most 
common form requiring surgical treatment, followed by mitral valve 
regurgitation, totalling around 6000 and 3900 cases per annum respectively 
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in the UK (118).  In both aortic and mitral valve surgery, intervention is 
performed to prolong life by preventing left ventricular injury, and to reduce 
distressing symptoms such as angina and dyspnoea. Valve disease and 
coronary artery disease frequently co-exist, mandating a joint procedure to 
repair or replace the affected valve alongside CABG surgery.  Percutaneous 
treatment for aortic and mitral valve lesions is now developing in some 
selected UK centres.  This obviates the need for a full thoracotomy and 
cardiopulmonary bypass, but the technique is currently only available in a 
handful of specialist centres.  Additionally, the current evidence base 
restricts this approach to include only patients at very high risk of death or 
serious disability following a conventional surgical approach (119).  It is likely 
to take some years to fully evaluate these minimally-invasive procedures, 
and there will be a further delay in availability of the service caused by the 
requirement to train interventional cardiologists in this technique. In the 
meantime a conventional surgical treatment is the best option for the 
majority patients. 
 
Circulatory support during surgery 
 
The majority of cardiac surgery in the UK is performed using 
cardiopulmonary bypass to oxygenate and circulate the blood during the 
operation.  Anticoagulated blood is diverted from the venous circulation 
using large bore tubes inserted into the right atrium or proximal vena cava.  
Having been routed through a filter, blood is cooled, oxygenated and 
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pumped back into the proximal aorta.  This allows cardioplegia to be used, a 
technique which results in an intentional cardiac arrest.  This gives the 
surgeon a motionless heart during the delicate phases of the surgery and 
thus facilitates the creation of anastomoses between conduit and native 
vessels.  It also reduces the risk of air entering the circulation and causing 
embolic damage such as stroke.  CABG comprises four main manoeuvres – 
i) surgical access to the thoracic cavity and connection to the perfusion 
circuit, ii) the establishment of cardiopulmonary bypass, iii) cross-clamping of 
the aorta and induction of cardiac arrest using a cardioplegia solution 
alongside cooling and iv) attaching the vascular grafts.  As well as an 
inflammatory response due to connection to the bypass circuit, and a risk of 
stroke from the procedures which involve instrumenting the aorta, direct 
myocardial injury is also seen in CABG surgery and is discussed below.  The 
procedures which require aortic surgery (e.g. graft attachment) all 
predispose the patient to the risk of stroke. At the end of the operation, 
normal heart rhythm is restored, and the patient is rewarmed.  As 
extracorporeal support is no longer required, it is “weaned” off and the 
access pipes are removed. 
 
Cardiac surgery is associated with significant morbidity and 
mortality 
 
The physiological and biochemical insults faced by cardiac surgical patients 
in the perioperative phase can translate into adverse clinical events. A recent 
international prospective observational study suggests that composite 
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morbidity and mortality in CABG patients ranges from 12-24% (120).  As well 
as general systemic insults including exposure to the bypass circuit, direct 
cardiac manifestations include coronary atheroembolic events with 
downstream myocardial necrosis following instrumentation of the coronary 
arteries, and direct myocardial injury from handling or over-distension.  
Some perioperative degree of myocardial necrosis is ubiquitous following 
cardiac surgery. 
 
Direct myocardial ischaemia-reperfusion injury occurs during 
CABG 
 
Intermittent cross-clamping of the aorta, performed to allow the attachment 
of vascular conduits during CABG results in repeated pan-regional episodes 
of myocardial ischaemia-reperfusion injury, in addition to damage induced by 
direct surgical contact with the myocardium.  The extent of myocardial 
necrosis experienced during surgery can be quantified by measuring 
cardiac-specific markers such as troponins and myocardial-bound creatine 
kinase (CK-MB).  Recent clinical research has shown that perioperative 
release of troponin-T is associated with poorer short and long-term 
outcomes.  In a recent single centre prospective study of over 800 patients 
undergoing CABG, an elevated level of troponin-T when measured at 24 
hours was found to be an independent predictor of death, heart failure or 
need for inotropic support.  Conversely, a postoperative troponin-T below 
1.6ng/ml had a high negative predictive value for excluding post-CABG 
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complications, suggesting that interventions aimed at reducing perioperative 
myonecrosis may be clinically relevant (121).    Additionally, MRI techniques 
confirm that detectable myocardial scar is seen following 32% of myocardial 
revascularisation procedures, with a mean infarct mass of 5g.  This is 
associated with a three-fold increase in adverse events in this group (122) .  
Periprocedural myocardial injury is not limited to revascularisation by CABG, 
but also occurs in the setting of PCI, hence targeting treatments at 
periprocedural cardioprotection could have applicability in both clinical 
settings (123). 
 
Attempts to reduce perioperative myocardial injury: 
Optimal surgical revascularisation 
Following a paper published by the Cleveland Clinic in 1986, the use of an 
internal mammary graft in preference of a vein graft became standard 
practice.  Prior to this, it was standard practice to graft the left anterior 
descending artery with a saphenous vein graft.  This new approach lead to a 
significant reduction in death, late myocardial infarction, recurrent angina 
and the need for repeat surgery.  The benefits extend out to 10 years 
postoperatively (124).  Even fuller revascularisation can be performed using 
bilateral internal mammary artery grafts, and an early systematic review 
suggested better survival outcomes in these cases (125).  The prospective 
randomised multicentre international Arterial Revascularisation Trial recently 
published 1-year follow up data, comparing single versus bilateral arterial 
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grafts.  In this study, CABG patients were enrolled in 28 hospitals in seven 
countries. 3102 patients were randomly assigned to single (n = 1554) or 
bilateral IMA grafts (n = 1548). The mean number of grafts was 3 for both 
groups. Mortality was identical at 30 days and 1 year The rates of stroke, 
myocardial infarction, and repeat revascularization were also the same in 
both (126). The data confirm that this approach to maximal revascularisation 
is feasible though the authors accept it is technically more challenging.  
However, uptake of the technique amongst cardiac surgeons is slow, with 
less than 10% of patients receiving the technique in Europe (127). 
 
Off-pump surgery 
 
In the mid-1990s, CABG without the use of cardiopulmonary bypass circuit 
started to become established – “off-pump” CABG (OPCABG) or “beating 
heart” surgery.  OPCABG was believed to reduce the perioperative systemic 
inflammatory response syndrome, and some studies showed reduced levels 
of circulating inflammatory markers in this setting (128-130).  The cerebral 
insult accrued during CABG, which can lead to long-term cognitive 
abnormalities, was also perceived to be related to exposure to the bypass 
circuit, and could thus potentially be diminished by OPCABG (131-133).  
Intraoperative haemodynamic parameters and some technical aspects of 
cardiac handling, especially in regard to accessing the posterior aspect of 
the heart for grafting the circumflex vessel and its branches, may also be 
improved by using OPCABG (134;135).  In some settings, OPCABG was 
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shown  to confer a shorter in-hospital stay, better renal parameters, reduced 
operative blood loss and reduced perioperative myocardial injury in 
comparison with conventional “on-pump” surgery (136) and  a reduction in 
operative mortality amongst OPCABG cohorts was noted  (137).  Despite 
these potential advantages, OPBACG remains a “niche” tool, performed by a 
minority of UK surgeons in a subset of highly selected cases (138).   
However, the acute (139) and longer-term (140) patency of grafts performed 
during OPCABG has recently been questioned, Data from a recent 
prospective, randomised, controlled, single-blind study of 2203 patients 
undergoing CABG  suggest a poorer outcome with OPCABG, even in 
experienced hands (141).  The investigators showed worse composite 
adverse outcome and poorer graft patency in the OPCABG group.  
Incomplete revascularisation at the time of surgery, more common with 
OPCABG, has also been shown to be associated with a worsening in mid-
term mortality (142).  It remains to be seen whether OPCABG will increase in 
popularity, or wither on the vine.  With the exception of the fledgling 
percutaneous interventional valve techniques outlined above, valve surgery 
always mandates full cardiopulmonary bypass.  Whatever the case, it seems 
likely that, even with a fully optimised surgical technique, patients will still be 
exposed to some degree of cardiac and systemic insult if we are to perform 
these major procedures (130).  Surgical “fine-tuning” alone is unlikely to 
provide the answers, particularly as cardiac surgeons face an ageing cohort 
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of patients with multiple comorbidities, leading to a higher incidence of high-
risk cases (143). 
 
Cardioprotective strategies during cardiac surgery: 
Perioperative ischaemic preconditioning 
 
First characterised in humans by Yellon et al in 1993, IPC was applied in the 
context of applying intermittent cross-clamping of the aorta following the 
establishment of cardiopulmonary bypass.  Two, three minute cycles of 
aortic cross-clamping were performed as the preconditioning stimulus, 
applied at two minute intervals to allow intermittent reperfusion.  They 
demonstrated  higher levels of ATP in the IPC cohort  (144).  Following this, 
a subsequent study confirmed lower levels of perioperative cardiac 
biomarker release at 72 hours post-surgery, specifically troponin-T (145).  
However, cross-clamp fibrillation remains unpopular as repeated aortic 
handling may induce stroke, especially in the increasingly older cohort of 
patients who may exhibit extensive calcification of the vascular tree. 
 
Remote ischaemic preconditioning during cardiac surgery 
 
Remote ischaemic preconditioning (RIPC) refers to the cardioprotective 
effect seen where the preconditioning stimulus is applied to an organ or 
tissue remote from the heart itself (146).  First described in canine hearts, 
the investigators reported that, by intentionally applying prior circumflex 
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territory ischaemia, the effects of a subsequent left anterior descending 
occlusion were ameliorated, evidenced by a reduced final infarct size (67).  
Cardioprotective effects are also seen where a preconditioning (ischaemic) 
insult is applied remote from the heart itself.  Pell et al, using a rabbit model,  
demonstrated that intermittent renal ischaemia could be used to induce 
cardioprotection, and linked this with activation of adenosine receptors and 
K-ATP channels (147).  Subsequently this was also demonstrated with 
surgically-induced mesenteric (148) and gastrocnemius muscle ischaemia 
(149), again in animal models.  In the setting of human patients undergoing 
cardiac surgery, Kharbanda and colleagues demonstrated a more useful and 
clinically applicable approach, avoiding the need for surgically-induced 
remote ischaemia. Using transient limb ischaemia of the forearm, they were 
able to demonstrate a reduction in ischaemia-reperfusion injury-induced 
endothelial dysfunction of the contralateral limb in human volunteers.  Using 
a pig model they confirmed that this could translate into a reduced 
myocardial infarction size (150).  In 2007, Hausenloy and colleagues 
performed a randomised controlled trial of the effects of RIPC on myocardial 
injury in patients undergoing CABG.  The results confirmed a 43% reduction 
in absolute troponin-T release (151).  The mechanism through which this 
protective effect is gained, however, remains unclear, and it is likely that a 
neural or hormonal pathway, or a combination if the two, exists to transmit 
the cardioprotective signal to the myocardium (146).  Despite good evidence 
for RIPC, and little likelihood of harm, it remains little used clinically and data 
48 
 
from outcome studies are awaited.  Such a study is being undertaken by 
Yellon‟s group at University College London and University College London 
Hospitals.  This is entitled the Effect of Remote Ischaemic Conditioning in 
Coronary Artery Bypass Graft (ERICCA) study, and it is a randomised, 
double-blind placebo controlled trial  (152). 
 
Pharmacological preconditioning in CABG 
 
The administration of a drug which might reduce perioperative myocardial 
injury is an attractive prospect, and has been intensively studied to date.  
Heavily implicated in cardioprotective cascades, adenosine has been shown 
to act as a preconditioning mimetic, reducing perioperative biomarker 
release (153;154).  A recent small prospective randomised study using 
adenosine alongside cold cardioplegia suggests that it may reduce troponin-I 
release, reduce the release of inflammatory mediators IL-6 and IL8, and 
reduce myocardial cellular damage. There was also evidence of a reduction 
in mitochondrial damage in the adenosine cohort (155).  However, at the 
doses required to produce a meaningful effect, adenosine causes significant 
side effects including bradycardia and hypotension.  Indeed, it is used to 
provoke ischaemia by inducing coronary vascular hyperaemia in testing for 
coronary insufficiency, so thus may actually be inducing perioperative 
ischaemia.  Perhaps, in this setting, we might be seeing pharmacological 
induction of ischaemia similar to pre-infarct angina, and it is this which 
confers protection, rather than the effect of the adenosine itself.  In an 
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attempt to avoid administration of exogenous adenosine, Mangano used 
acadesine, a modulator of endogenous adenosine, in a large randomised 
controlled multicentre study of 2698 patients undergoing elective CABG.  In 
those patients suffering from postoperative myocardial infarction (3.7% of the 
cohort), 2-year survival was shown to be improved, but there was no 
difference in the non-MI group (156).  This is in keeping with the modification 
of myocardial infarction by adenosine seen in studies of its acute 
cardioprotective effects in humans undergoing reperfusion by thrombolysis 
(157) and PCI (158;159).   
In the GUARDIAN clinical study, the sodium-hydrogen exchange inhibitor, 
cariporide initially looked promising in terms of a small improvement in early 
mortality and myocardial infarction (160).  However, the subsequent larger 
EXPEDITION trail confirmed that these findings did not persist beyond the 6 
month point, and confirmed the unwanted complication of an increase in 
cerebrovascular mortality associated with the drug (161).  
   
Statin therapy and perioperative cardioprotection - the data so far 
 
Fully established in the primary (87) and secondary prevention roles 
(90;162), investigators have started to explore the potential value of statins 
in clinical cardioprotection (163;164).   
In 2000, Dotani et al reported the findings of a West Virginia University 
Hospitals retrospective analysis of the effects of perioperative statin therapy 
and cardiac outcomes following CABG.  Out of 323 cases analysed, 104 
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patients were taking statins, of which 80% were using atorvastatin.  There 
was a striking reduction in composite adverse events in the statin group 
(18% versus 57%, p<0.0001), and a significant reduction in both early (0% 
vs. 3.7%, p=0.05%) and late death.  However the cohorts here were 
relatively small, and the authors concluded that further prospective 
randomised data should be sought (165).  
 
Lazar performed a study of pigs undergoing an acute ischaemic coronary 
insult followed by cardiopulmonary bypass and surgical revascularisation. 21 
days of pretreatment with atorvastatin 40mg (in 35 kg animals) was shown to 
reduce perioperative haemodynamic instability, reduce arrhythmias, improve 
ventricular wall motion scoring and resulted in a smaller final infarct size than 
placebo (21±2% vs. 41±2%, p=0.0001), despite the area of myocardium at 
risk being the same across the groups.  However, the model used is not a 
true simulation of elective CABG, with some features of the study being 
more a model of acute ischaemia-reperfusion injury rather than a pure 
perioperative cardioprotection model.  CABG is simply not used for acute 
revascularisation in the context of acute total coronary occlusion.  However, 
the study usefully confirms that oral treatment with atorvastatin can induce a 
cardioprotected state (166). 
 
A predefined subset analysis of 5436 patients in the prospective McSPI 
Epidemiology II multicentre study confirmed that preoperative statin therapy 
was associated with a significant reduction in the risk of early cardiac death 
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(0.3% vs. 1.4%, p<0.03) after elective CABG (Adjusted odds ratio 0.25; 95% 
confidence intervals 0.07-0.87).  Additionally, discontinuation of statin 
therapy after surgery was also noted as to be independently associated with 
an increased risk of late postoperative mortality compared with those 
receiving uninterrupted statin therapy  (1.91 versus 0.45, p<0.01).  These 
data further outline the importance of perioperative statin therapy (167). 
 
Two randomised controlled trials of atorvastatin followed, one of which 
demonstrated that preoperative atorvastatin was able to reduce the 
incidence myocardial dysrhythmias, specifically atrial fibrillation (168) .  The 
second demonstrated that atorvastatin therapy was able to reduce serum 
inflammatory cascade markers (neutrophil CD11b expression, IL-6, & IL-8), 
although interestingly, not the incidence of systemic inflammatory response 
syndrome (169). 
 
In 2008, a single-centre retrospective study of 1389 consecutive elective 
cardiac valve operations at Brigham and Womens‟ Hospital, Boston, 
demonstrated that 26% were taking statins at the time of their surgery. (54% 
atorvastatin, 34% simvastatin).  The operative mortality rate was 0.8% in the 
statin cohort and 2.3% in the non-statin group.  However, a trend towards 
lower stroke rates emerged in the statin group.  There was no evidence to 
point towards any particular underlying mechanism of the improved 
outcomes seen (170). 
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More robust clinical evidence in support of reduced perioperative myocardial 
necrosis was afforded by Mannacio‟s study, also in 2008.  Performed in an 
Italian centre, 200 consecutive patients undergoing elective CABG were 
enrolled in a randomised, double-blind fashion.  Study inclusion criteria were 
highly selective in order to preserve study group homogeneity.  In the 
intervention arm, rosuvastatin 20mg daily was prescribed 7 days prior to 
surgery, irrespective of lipid status.  All aspects of the anaesthesia, surgery 
and subsequent management on the surgical critical care unit were 
standardised. The results demonstrated that patients receiving a statin 
required less inotropic support,  suffered  less postoperative atrial fibrillation 
and required a mean of 1 day less hospitalisation, than did the control group.  
There was also a reduction in high-sensitivity C-reactive protein following 
statin therapy.  Importantly, myocardial damage was reduced in the statin 
group, with reductions in peak levels of troponin-I (0.16±0.015 versus 
0.32±0.26 ng/ml, p=0.0008), CK-MB (3.9±3.3 versus 9.3±8.1 ng/ml).  These 
data further suggest that the role of statins in this cohort is due to a direct 
cardioprotective effect, rather than a more general anti-inflammatory 
pleiotropic benefit  (171). 
 
A Parisian study of consecutive elective high-risk cardiac valve surgery 
patients assessed preoperative statin therapy and outcome variables.  
Following multivariate and propensity-adjusted regression analysis 
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regression of 422 cases, the three mortality risk factors identified were lack 
of statin use, poor ventricular function and pulmonary hypertension.  Statins 
were associated with a significant reduction of postoperative mortality (odds 
ratio of 0.41, p=0.04), further adding weight to their value in the setting of 
cardiac surgery (172;173). 
 
A meta-analysis of over 30,000 patients from 19 studies by Liakopoulos 
confirms that statin therapy exerts a significant clinical benefit on early 
postoperative outcomes in cardiac surgical patients (174).  A further meta-
analysis suggests a 25% relative reduction in mortality may be achieved by 
the use of preoperative statin therapy.  Surprisingly, the authors stopped 
short of advocating routine preoperative statin therapy (175). 
 
Subsequent to these, further data confirming that atorvastatin can reduce 
perioperative myocardial injury comes from a small prospective controlled 
study of 40 patients undergoing CABG.  The investigators demonstrated a 
reduction in postoperative biomarker release following the preoperative 
administration of atorvastatin (20mg/day).  24 hours  after the surgery, 
troponin I and CK-MB levels were significantly lower in the atorvastatin 
group: for CK-MB levels, 12.9±4.3 versus 18.7±7.4 ng/ml, (p=0.004); for 
troponin I levels, 1.7±0.3 versus 2.7±0.7 ng/ml (p < 0.001). In addition, 
atorvastatin use was associated with a decrease in the duration of critical 
care unit admission (176).  The same research group have previously shown 
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reduced  high-sensitivity C-reactive protein and IL-6 levels following 
preoperative atorvastatin (20mg/day) in a similar setting (177). 
 
Underlying Mechanisms 
 
Possible underlying mechanisms for the perioperative benefits of statins 
include a range of pleiotropic actions.  These include anti-inflammatory 
effects, antithrombotic and antiplatelet effects, and atheromatous plaque 
stabilisation (163;164;178;179).  However, whilst these could be seen to 
contribute to improved haemodynamic variables and perhaps reduce critical 
care admission duration, they are unlikely, per se, to contribute to any 
reduction seen in perioperative myocardial ischaemia-reperfusion injury (96).   
 
Chronic statin administration and loss of cardioprotection 
 
Whilst the lipid-lowering effects of statins increase in the weeks following 
administration, it is understood that the cardioprotection offered against 
ischaemia-reperfusion injury wanes over time.  Atorvastatin has been shown 
to be cardioprotective and reduce ischaemia-reperfusion injury when given 
acutely during the reperfusion phase of an experimental myocardial 
infarction (72)  In a rat model, Mensah demonstrated that, after 1-2 weeks 
therapy with 20mg/kg atorvastatin, the ability to cardioprotect against 
myocardial infarction was lost.  An additional 40mg/kg high-dose repeat 
exposure to atorvastatin, however, was able to “recapture” the lost 
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cardioprotective effect, when given 3-4 hours prior to myocardial ischaemia-
reperfusion injury.  Analysis of levels of phosphatase and tensin homolog 
deleted on chromosome ten (PTEN) – a ubiquitously present “house-
keeping” dual phosphatase - using a Western blotting immunochemistry 
technique were performed.  These confirmed that chronic administration of 
atorvastatin leads to elevated levels of PTEN (180).  Atorvastatin is known to 
induce cardioprotection acutely through activation of the PI3K/Akt pathway 
(72).  This is a short term pro-survival pathway, with an anti-apoptotic effect 
(181-183).  However, unopposed long term up-regulation of this enzyme 
cascade would induce hypertrophy, and in some tissue lines may be 
oncogenic (184-188).  PTEN acts as an inbuilt down regulator of the 
PI3K/Akt system, which prevents the activated enzymes remaining in a 
phoshorylated state long-term.  In terms of inhibiting long-term 
cardioprotection conferred by statin therapy, PTEN has been termed the 
“Achilles heel” of myocardial ischaemia-reperfusion injury (189).  The 
occurrence of this phenomenon in human myocardium has not been 
established.   Similarly, the ability to “recapture” cardioprotection  by using a 
high dose of statin prior to an ischaemia-reperfusion insult remains a 
concept unproven in humans, although clinical studies of periprocedural 
biomarker release following urgent PCI hint that this might be the case 
(178;190). 
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Summary and basis for experimental studies 
 
The beneficial effects of statin therapy during the perioperative phase could 
be due to a variety of pleiotropic actions.  However, data exist which support 
the likelihood that some of the benefit is derived from a reduction in 
perioperative myocardial ischaemia-reperfusion injury.   
 
Any protection against myocardial ischaemia-reperfusion injury afforded by 
atorvastatin should reduce following chronic administration, and it is 
unknown whether high dose oral administration to human subjects can 
recapture cardioprotection in myocardial tissue.  These issues will form the 
basis for experimental studies outlined below. 
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Hypertrophic Cardiomyopathy and Cardioprotection  
Background  
First formally characterised as a clinical entity in the late 1950s (191), 
hypertrophic cardiomyopathy (HCM) is a genetically inherited disorder 
characterised by unexplained hypertrophy of the left ventricle.  Affecting up 
to 1 in 500 of the general population (192-194), HCM is the most common 
inherited cardiovascular disorder.  Although it can manifest at any age, it is 
one of the most common causes of sudden death in young people and 
athletes (195). The clinical syndrome is caused by mutations in genes which 
encode cardiac sarcomeric proteins.  Key features include myocardial 
hypertrophy, myocyte disarray and fibrosis, and small vessel coronary 
disease.  HCM occasionally may present in association with other diseases 
such as Noonan‟s syndrome, mitochondrial disorders, and metabolic 
disorders such as Anderson-Fabry disease. 
 
Genetic Basis 
The first step in the pathogenesis of HCM involves mutation-induced 
dysfunction of the sarcomere – the functional subunit responsible for 
myocardial contraction (194;196).  HCM is inherited as an autosomal 
dominant condition, but with significant and expanding heterogeneity (197).  
Over 1000 mutations in 13 or more genes have been identified to date, 
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encoding for a variety of proteins associated with myocyte structure and 
function (196;198;199).  The most common HCM-causing genes encode ß-
myosin heavy chain, cardiac troponin T and myosin-binding protein C, and 
these genes account for the bulk of cases.  A smaller number of cases are 
due to mutations in genes encoding cardiac troponin I, myosin light chains, 
titin and α-myosin heavy chain.  Many other genes and mutations are yet to 
be identified.  Genetic testing of subjects using DNA analysis for mutant 
genes is possible, and provides a definitive diagnosis.  However, due to its 
complexity and costs it is not current clinical practice, and the diagnosis is 
usually made based on clinical criteria in the majority of cases. 
 
Clinical Diagnosis 
Clinical examination may reveal features of left ventricular outflow tract 
obstruction, evidenced by a bifid arterial pulse and a systolic murmur audible 
on auscultating the chest with a stethoscope.  However, true resting left 
ventricular outflow tract obstruction is only present in around 25% of cases of 
HCM (200-202), so these are unreliable markers in isolation.  Baseline 
electrocardiography is abnormal in 75% to 95% of HCM patients, commonly 
demonstrating high voltages indicative of left ventricular hypertrophy, 
interventricular conduction defects (such as right or left bundle branch 
block), PR interval shortening and ST segment and T wave abnormalities 
(203-205).  Formal diagnosis is achieved using 2-dimesional 
echocardiography, which confirms a hypertrophied, non-dilated ventricle, at 
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the same time excluding other structural causes of hypertrophy such as 
intercurrent aortic valve disease (206).  Additionally, echocardiography is 
used to confirm and measure the presence of any left ventricular outflow 
tract obstruction, and assess for systolic anterior motion of the mitral valve – 
both hallmark features of HCM.   
 
 
Figure 1.1 – post-mortem specimen showing massive hypertrophy of the 
interventricular septum and left ventricle, resulting in near obliteration of the 
left ventricular cavity when compared to the right ventricle (identified by 
forceps on left of image). Reproduced courtesy of Pinpoint Scotland Ltd. 
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Histological abnormalities 
Microscopically, left ventricular tissue is hypertrophied, and disarrayed with 
chaotic cellular alignment and multiple intercellular connections which are 
not found in normal myocardium (207).  This cellular disarray may be focal or 
more generalised throughout the left ventricle, and frequently also involving 
the right ventricle  
 
Enhanced oxidative stress 
Experimental animal models of left ventricular hypertrophy induced by 
pressure overload, for example using aortic banding to increase ventricular 
afterload, have demonstrated elevated markers of myocardial oxidative 
stress suggesting this is an important component in the pathogenesis (208-
210) .  One clinical study of HCM patients with LV dysfunction confirmed 
increased expression of 4-hydroxyl-2-nonenal-modified protein, a marker of 
myocardial oxidative stress (211).  A recent study in patients with HCM and 
preserved LV function assessed serum levels of 8-isoprostglandin F2α as a 
marker of oxidative stress and found HCM patients had significantly elevated 
levels compared with matched, non-HCM control subjects.  Interestingly, the 
level of oxidative stress positively correlated with anatomical and 
haemodynamic indices of left ventricular outflow tract obstruction (212).  
Pressure overload triggers nitric oxide synthase-3 uncoupling, generating a 
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significant burden of reactive oxygen species (213). In experimental settings, 
antioxidant therapies such as tetrahydrobiopterin and N-actetylcysteine have 
been shown to reduce nitric oxide synthase-3 uncoupling, inhibit reactive 
oxygen species generation and block or reverse maladaptive changes  in 
hypertrophic hearts(214;215) .  Oxidative stress has also been shown to 
induce perivascular inflammation and cardiac fibrosis – both present in the 
setting of HCM (216). 
 
HCM generates a state of chronic regional myocardial ischaemia 
The increased myocardial mass leads, in turn, to an increase in basal 
myocardial oxygen requirements .  Extravascular compressive forces, 
applied to the perfusing blood vessels by the abnormally bulky myocardium, 
reduce myocardial perfusion and can compromise flow in large septal 
perforator branches and even major epicardial vessels.  In addition, the 
intramural coronary vessels are of relatively small calibre due to medial 
hypertrophy (217;218).  At myocyte level, disarray leads to inefficient 
contraction, leading to further circulatory demands.  These multiple factors 
combine to result in reduced coronary vasodilator flow reserve (219-224) 
and a myocardium which is frequently exposed to ischaemia, resulting in 
myocyte necrosis and scarring (225).  The degree of circulatory impairment 
has been shown to be clinically significant, and correlates with long term 
adverse event rates (226).   
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HCM renders the myocardium more sensitive to ischaemia 
Multiple co-existing factors render the HMC-affected heart more susceptible 
to the effects of ischaemia than normal heart tissue (227-229).  
Abnormalities of myocardial metabolism, calcium handling, a chronic 
inflammatory response, sympathetic nervous system and renin-angiotensin 
system activation co-exist in cardiac hypertrophy, and contribute towards 
and increased sensitivity of hypertrophied myocardium to ischaemia-
reperfusion injury (230-232).  Uncoupling of energy substrate use, with low 
glucose oxidation, and higher rates of glycolysis have been observed in 
hypertrophied rat hearts, leading to reduced functional recovery after an 
ischaemic insult   (233;234).  Reduced sarcosplasmic reticulum calcium 
ATPase activity leads to cellular calcium overload, and this subsequently 
further impairs post-ischaemic recovery (230;235).  Additionally, the effects 
of powerful means of cardioprotection, such as pharmacological inhibition of 
the mitochondrial permeability transition pore, may not operate in the setting 
of some pathologies (229;231).  Specifically it is not known whether the 
opportunity to manipulate this protective mechanism exists in HCM. 
 
HCM frequently co-exists with coronary artery disease 
 
First reported in an angiographic case series by Gulotta over 30 years ago, 
HCM and coronary artery disease can frequently co-exist, especially in older 
cohorts (236).  In those over 45 years of age, significant angiographic 
epicardial lesions can be found in up to 24% of HCM cases (237-240).  The 
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burden of stenotic lesions required to cause ischaemia is likely to be much 
lower in the setting of HCM, due to the pre-existing presence of reduced 
coronary flow reserve, as outlined previously (241).  The paucity of long term 
outcome data in this important group of patients was recently addressed by 
Sorajja et al, who performed a retrospective case analysis of adult HCM 
patients undergoing coronary angiography over a 28 year period (242).  Of a 
final study population of 433 patients, 26% has severe coronary artery 
disease, 27% mild-to-moderate disease, and 47% had normal angiograms.  
Patients with coronary artery disease were more likely to have co-existing 
risk factors such as hypertension, diabetes and stroke than those without 
coronary artery disease.  The 10-year survival rate in those with HCM and 
severe coronary disease was startlingly low at 46%, despite these patients 
having good ventricular systolic function.   The sudden cardiac death rate 
was 2.1%, which represents a doubling of that expecting in the background 
HCM population.  All-cause annual mortality was markedly elevated at 6.65 
which represents a doubling of the rate of death even when compared 
against „complicated‟ HCM tertiary unit reported annual data (243-245) 
 
Available supportive medical and surgical therapies for HCM  
The overall annual mortality rate in patients with HCM is similar to the 
general population, and is around 1% (246).  Many patients experience a 
normal life expectancy despite having the condition.  However, a high-risk 
subgroup of younger patients exists, in which mortality rates of up to 6% per 
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year could be expected (206).  To avoid sudden cardiac death from 
arrhythmia, risk stratification is performed to identify these high-risk 
individuals as they would benefit from an implantable cardioverter-
defibrillator (ICD).  Clinical markers of high-risk include a family history of 
sudden death, syncope, nonsustained ventricular tachycardia and a poor 
haemodynamic response to exercise (247).  Risk assessment can be further 
refined by the use of cardiac magnetic resonance imaging to detect scar, 
which can suggest a 5 year probability of sudden cardiac death of 11%, 
versus 0.7% where scar is absent (248).  Subcutaneously implanted ICDs 
allow for advanced pacing and cardioversion therapies to be delivered 
immediately should potentially fatal arrhythmias such as ventricular 
tachycardia or fibrillation ensue, with the aim of avoiding cardiovascular 
collapse, hypoxic brain injury and subsequent death.   
Drug therapy to improve symptoms is typically aimed at reducing the left 
ventricular outflow tract gradient.  A treatment regimen might typically 
include the use of negatively inotropic agents such as ß-blockers, verapamil 
or disopyramide.  These agents are thought to enhance ventricular filling, 
decrease myocardial oxygen demand and increase myocardial perfusion.  ß-
blockers are considered first-line therapy, with the calcium channel blocker 
verapamil used where ß-blockers are either not tolerated or contraindicated, 
or where diastolic dysfunction is the predominant feature.  Disopyramide, a 
class Ia sodium channel blocking antiarrhythmic,  is usually reserved for 
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cases with severe functional limitation unresponsive to other agents (206).  
None of these agents has any proven prognostic benefit. 
 
For severely symptomatic patients with prominent septal hypertrophy, 
interventional cardiology techniques can be employed to improve left 
ventricular outflow.  Alcohol septal ablation can be performed 
percutaneously and will aid with breathlessness or syncope in carefully 
selected cases. The technique involves intubation of a large septal artery 
under echocardiographic and angiographic guidance, followed by injection of 
alcohol to effectively induce a limited infarction.  The resulting loss of 
myocardial mass within the target area improves flow and relieves 
symptoms, with procedural success in over 80% of cases (206;247;249).   
 
 In refractory cases, surgical excision of excess bulky septal tissue can be 
performed with good results, though this technique is highly invasive and 
requires full cardiopulmonary bypass and a thoracotomy.  It is most suited to 
cases where surgery is required concomitantly to treat valve lesions or co-
existing coronary artery disease (206;247).   
 
Disease Modification – the current state of play 
 
Despite recent advances in cardiovascular medicine, no pharmacological 
therapies currently exist which can inhibit or actually reverse disease 
progression.  Gene therapy has been suggested as the most likely source of 
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a meaningful disease-modifying therapy, but this is currently a long way from 
being a useful clinical tool.  The condition is incompletely characterised in 
genetic terms, the clinical course is not fully documented, and there is a 
paucity of evidence-based therapy available (247;250).   
 
The potential roles for statin therapy in HCM 
 
Statins and cardiac hypertrophy  
 
Cardiac hypertrophy and interstitial fibrosis are major determinants of 
morbidity and mortality from disease processes other than HCM, and in 
particular are found in hypertensive heart disease, and coronary artery 
disease (251;252).  This has led to investigation of the pleiotropic effects of 
statin therapy in this context, in addition to their well-documented mortality 
and morbidity effects due to improved lipid profile.   
In a study of rats with angiotensin-induced hypertension, treatment with 
simvastatin attenuated the development of hypertension, inhibited left 
ventricular mass increase and reduced circulating markers of oxidative 
stress (253).  Laufs et al treated spontaneously hypertensive rats with 
atorvastatin, and their findings suggested that inhibition of pro-hypertrophic 
small GTP binding proteins Rac1 and RhoA may be responsible for statin-
induced reduction of left ventricular mass (254).  In a magnetic resonance 
study of left ventricular hypertrophy in rats exposed to surgically-induced 
myocardial infarction, Nahrendorf et al demonstrated that cerivastatin 
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attenuated post-infarction left ventricular hypertrophy and improved cardiac 
output.  Interestingly, the protective statin effect was abolished by nitric oxide 
synthase inhibition with L-NAME (255).  These results are further supported 
by the work of Luo et al, who showed that simvastatin can inhibit hypertrophy 
in a rat model of aortic stenosis (256).  Indolfi et al implicated Ras activation 
as an important factor in the prevention of cardiac hypertrophy by 
simvastatin, using a pressure overload model of ventricular stress (257), and 
Chen et al confirmed that statins prevent hypertrophy in a rat model of 
hypertrophy (258). 
 
Clinical trials of statins in the anti-hypertrophy role 
 
Su et al examined the effects of pravastatin 10mg daily  on left ventricular 
hypertrophy in drug-naive patients with an adverse lipid profile and essential 
hypertension in a small, prospective clinical study.  There was a significant 
excess reduction of left ventricular mass index in patients treated with statin 
therapy, 11% over and above that achieved by maximal antihypertensive 
therapy.  The authors suggested inhibition of angiotensin II mediated 
transcription factors as a possible mechanism for the anti-hypertrophy effect 
(259;260).  In a clinical study of 300 angina patients with angiographically 
confirmed coronary stenosis, Nishikawa et al reported that therapy with 
pravastatin or simvastatin significantly reduced left ventricular mass 
evidenced by follow-up echocardiography by 14.7%, compared to controls 
(261). 
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Studies of statins in animal models of HCM 
 
In an animal study investigating the antioxidant effects of statin therapy on 
cardiac myocyte hypertrophy, Takemoto et al treated neonatal rat 
cardiomyocytes with angiotensin II to increase reactive oxygen species 
production and subsequently induce hypertrophy, with and without 
simvastatin 5 µM.  In the simvastatin treated cells, cardiac myocyte 
hypertrophy was inhibited, due in part to inhibition of isoprenoid synthesis, 
Rho gerenylgeranylation and reactive oxygen species production (262).    
Patel et al studied a ß-myosin heavy chain transgenic rabbit model of human 
HCM which expresses cardiac hypertrophy, interstitial fibrosis, myocyte 
disarray and cardiac dysfunction.  Administering simvastatin 5mg/kg per day 
for 12 weeks induced regression of hypertrophy and fibrosis and improved 
cardiac function (263).  Using the same transgenic rabbit model, Senthil et al 
later showed that that treatment with atorvastatin 2.5 mg/kg lead to beneficial 
effects over and above the 49% reduction of serum total cholesterol levels 
achieved.  Multiple markers of cardiac hypertrophy were used to assess the 
effects of therapy, including echocardiographic assessments of left 
ventricular mass, histological studies of myocyte size, expression of 
molecular markers of hypertrophy and fibrosis and expression of oxidative 
stress response genes.  At organ, cell and molecular levels, atorvastatin 
therapy was shown to reduce cardiac hypertrophy after a 1-year observation 
period  (264).  Importantly, there was a reduction in left ventricular mass 
index of ~30%. However, it is important to note that, unlike the clinical cohort 
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of HCM patients exposed to experimental studies, the intervention arms in 
these two studies consist of a genetically homogenous group with a 
predefined  defect.  The possibility exists that this effect may be less 
significant where another gene defect is present. 
 
Clinical trials of statins on HCM 
 
Clinical trials of statin therapy in HCM have, however, been inconclusive to 
date.   In a single-centre randomised placebo-controlled double-blind pilot 
study, Bauersachs et al treated 11 HCM patients with atorvastatin 80mg 
daily for 9 months alongside placebo-treated controls.  Using 
electrocardiography, echocardiography and cardiac magnetic resonance 
imaging they were unable to demonstrate a significant improvement in left 
ventricular mass or other associated indices following statin therapy.  Only 
intended as a pilot study, the study design was underpowered to 
demonstrate anything other than a major difference in the two cohorts.  
Additionally, the number of patients taking calcium antagonists was almost 
doubled in the placebo arm, and this may have masked a possible treatment 
effect from statin therapy.  Therapy was also relatively short in terms of the 
natural history of HCM, which evolves over several years, with final follow-up 
after only 9 months of therapy. 
 
More recently, Nagueh et al performed a feasibility study in 21 HCM 
patients.  After enrolment, atorvastatin was administered at 20mg per day for 
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3 months, increasing to 40mg per day for a further 3 months  then continuing 
at  80mg daily for 18 further months.  At the 2 year point, the dropout rate in 
the atorvastatin arm was exceptionally high compared to previous statin 
studies, at over 50%. However, the authors explain this was mainly due to 
patients‟ lack of perceived clinical benefit, and no major adverse effects were 
seen.  Although no significant benefits were seen in terms of cardiac 
hypertrophy, it is interesting to note that reported exertional chest pain was 
markedly reduced, from 33% at baseline to 0% at 24 months.  
 
Difficulties inherent in clinical studies of human HCM 
 
The absolute numbers of patients investigated in these clinical trials are 
small.  It may be that they simply suffer from inadequate power with which to 
detect a difference.  Also, some of the difficulties lie in the genetic and 
phenotypic diversity of causal mutations and pathways involved in the 
pathogenesis of HCM in humans.  This contrasts with the animal models 
where the subjects have a homogenous background, caused by a pre-
specified genetic lesion. 
Measurement of left ventricular hypertrophy, especially by 
echocardiography, is not an exact science, and the tolerances allowed, 
combined with scan reporting inter-operator variances could have hidden a 
difference.  With cardiac magnetic resonance imaging this should become 
less of an issue (265), but technical scan reporting differences will still 
remain, even if all scans are done in one lab by one operator. 
71 
 
Rho and Rac signalling pathway activation, inhibited by statins, whilst 
important in some genetic forms, may not be activated in all forms of HCM 
caused by some genetic variants, and thus beneficial statin effects may not 
be present in all forms of the disease.  Also unknown is whether the 
pleiotropic beneficial effects of statins are truly a group-effect, or merely 
limited to a few agents. 
Even in the setting of prospective randomised clinical trials, the low overall 
event rate in the HCM population means that, to demonstrate a positive 
treatment effect, multi-centre studies would be needed, and follow-up needs 
to encompass many patients for many years, in order to accrue enough 
objective outcomes and clinical events.  A recent working group highlighted 
the urgent need to identify putative targets for intervention in HCM (250) 
 
Statins role may be more than anti-hypertrophy in HCM 
 
Are the beneficial effects of statins limited to an anti-hypertrophy role, or 
could they be due to inherent cardioprotective effects, protecting the sub-
optimally perfused myocardium from the effects of ischaemia-reperfusion 
injury?  If the anti-anginal effect seen in Nagueh‟s study is real, this would 
support this possibility.  Modification and mitigation of ischaemia-induced 
injury in this setting, and protection from ongoing, chronic injury, with 
subsequent replacement of damaged areas by scar, termed replacement 
fibrosis, could be a potentially useful effect of statin therapy, and may modify 
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its clinical course (225).  However, the ability of statins to cardioprotect in 
HCM in this manner has not been investigated.  
 
Summary and basis for experimental studies 
 
As outlined above, coronary artery disease and HCM frequently coexist and 
protection of this highly vulnerable myocardium from ischaemia-reperfusion 
injury during periods of cardiopulmonary bypass and handling during surgery 
(e.g. during myectomy for HCM, valve surgery or concomitant bypass 
grafting) or during percutaneous coronary intervention has not been 
addressed or studied to date.  Potential therapeutic avenues leading to the 
ability to pharmacologically cardioprotect in the setting of HCM will be 
examined in the experimental studies described below. 
 
Introductory Summary  
 
Preconditioning and postconditioning are cardioprotective techniques which 
reduce myocardial damage due to ischaemia-reperfusion injury.  Both share 
activation of the RISK pathway as an effector mechanism (82), and their 
effects are focussed in the moments surrounding reperfusion (266;267).  
Activation of the RISK pathway mediates inhibition of the mPTP (65) and 
promotes myocyte survival.  In terms of using these modalities in the clinical 
setting of ACS, the requirement to apply a stimulus upstream makes 
preconditioning clinically irrelevant.  Postconditioning, despite positive 
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clinical data in its favour (81), has potential technical drawbacks which make 
it unattractive for the PCI operator. 
 
Atorvastatin, a potent statin in widespread clinical use (115;116), has been 
shown to activate the RISK pathway and to reduce infarct size in 
experimental settings (72;103).  The aim of any search for a cardioprotective 
strategy for use during ACS should focus on myocardial salvage, as final 
infarct size remains the most important determinant of future prognosis, (10-
12), and infarct reduction is key to improving survival, preserving left 
ventricular function and avoiding heart failure. 
 
The occurrence of myocardial damage during CABG surgery and PCI is well 
established and associated with deterioration in clinical outcomes (122;268).  
Atorvastatin has been shown to be clinically effective in reducing adverse 
events rates in both settings (102;163).  However, the mechanism by which 
this is achieved remains to be delineated.  Additionally, it is known that the 
anti-ischaemia-reperfusion injury effects of statins wane with time (180).  The 
ability to recapture cardioprotection by an additional top-up dose of statin, a 
proven concept in animal models, has not been confirmed in humans. 
 
In the sphere of HCM, the presence of chronic ongoing myocardial 
ischaemia is now well-established (225).  Myocyte death leads to fibrosis, 
adverse ventricular remodelling and worsens clinical outcomes.  The ability 
74 
 
of cardioprotective techniques (such as mPTP inhibition) to operate in HCM-
affected human cells has not been investigated.  Any protection possible 
could be exploited either to modify the disease process itself, or at least offer 
protection in the setting of ACS, CABG or other surgical intervention in these 
high-risk patients. 
 
This thesis contributes by exploring the role of atorvastatin in acute 
cardioprotection in human myocardium, assessing whether it is possible to 
recapture statin-cardioprotection in human tissue, examining the 
mechanisms of statin-cardioprotection in humans and delineating the role of 
the mPTP in the setting of HCM. 
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Chapter Two:  OBJECTIVES AND HYPOTHESES 
 
Overall objective 
The main objectives of these experiments were to elucidate whether it is 
possible to pharmacologically protect human myocardium from ischaemia-
reperfusion injury and oxidative stress using atorvastatin, in two distinct 
pathological settings.  Three separate hypotheses were formulated as a 
basis for these experimental studies : 
 
Hypothesis one 
Atorvastatin protects the human myocardium when administered at the onset 
of reperfusion by the activation of prosurvival signalling pathways including 
the RISK enzymes PI3K, Erk-1/2, and inducible nitric oxide synthase. 
 
This hypothesis was examined by: 
 
1. Investigating whether atorvastatin, given at the onset of reperfusion, 
protects the human atrial myocardium from simulated ischaemia-reperfusion 
injury. 
2. Investigating whether inhibition of PI3K and Erk-1/2 pathways could 
abolish any cardioprotective effect elicited by atorvastatin 
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3. Investigating whether inhibition of nitric oxide synthase isoforms could 
abolish any protective effect elicited by atorvastatin. 
 
 
Hypothesis two 
High treatment with atorvastatin, administered orally, recaptures additional 
cardioprotection when compared to background chronic statin therapy, 
acting by the activation of prosurvival signalling pathways including the RISK 
enzymes PI3K and Erk-1/2, and inducible nitric oxide synthase. 
 
This hypothesis was examined by: 
 
1. Investigating whether high-dose atorvastatin pretreatment in patients 
undergoing cardiac surgery protects the human atrial myocardium from 
simulated ischaemia-reperfusion injury compared with standard dose 
background chronic statin therapy. 
2. Investigating whether inhibition of PI3K and Erk-1/2 pathways at 
reperfusion could abolish any cardioprotective effects elicited by high-dose 
atorvastatin pretreatment. 
3. Investigating whether inhibition of nitric oxide synthase isoforms could 
abolish any cardioprotective effect elicited by high-dose atorvastatin 
pretreatment. 
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Hypothesis three 
Human ventricular myocardium in the setting of obstructive hypertrophic 
cardiomyopathy can be pharmacologically cardioprotected. 
 
This hypothesis was examined by: 
 
1. Investigating whether treatment with cyclosporin-A can delay 
mitochondrial permeability transition pore opening following oxidative stress 
in isolated human ventricular cardiomyocytes. 
2. Investigating whether treatment with atorvastatin can delay mitochondrial 
permeability transition pore opening following oxidative stress in isolated 
human ventricular cardiomyocytes. 
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Chapter Three:  GENERAL METHODS 
Introduction 
This chapter describes the human atrial superfusion model of simulated 
myocardial ischaemia-reperfusion injury.  Also described is the human 
isolated ventricular myocyte model of oxidative stress, including assay of the 
mitochondrial permeability transition pore  
The human atrial superfusion model of ischaemia-
reperfusion injury 
Study subjects 
 
Patients undergoing elective coronary artery bypass grafting (CABG) and/or 
cardiac valve repair at the Heart Hospital, University College London 
Hospitals NHS Foundation Trust, London, were screened for eligibility for 
these studies. 
 
Prior ethical approval for the study was obtained from the University College 
London/University College London Hospital Committee on the Ethics of 
Human Research, sub-committee alpha.  The ethical approval reference was 
REC 00/00275.  Fully informed consent was obtained at the time of 
admission to hospital, on the afternoon prior to surgery.  Patients were not 
approached for consent discussions or possible recruitment if they had 
79 
 
received sedatives or opiate medication, to ensure consent was fully 
informed. 
 
Exclusion criteria 
The following patients were excluded: 
1. Patients over the age of 79 years. 
2. Patients presenting with unstable angina – cardiac chest pain at rest or 
dynamic ST-segment ECG changes. 
3. Patients presenting with non ST-segment elevation myocardial infarction, 
i.e. an acute coronary syndrome presentation accompanied by a detectable 
troponin release. 
4. Patients with arrhythmias including any form of atrial fibrillation, atrial 
flutter or any ventricular arrhythmia. 
5. Patients taking primary antiarrhythmic drugs such as digoxin or 
amiodarone. 
6. Patients with impaired left ventricular function (EF<50% on recent 
transthoracic echocardiogram) or assessed as impaired on perioperative 
transoesophageal echocardiogram), or presenting with cardiogenic 
pulmonary oedema. 
7. Patients with renal impairment (estimated glomerular filtration rate 
<60ml/min). 
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Patient profiles 
A total of 68 patients were recruited into these studies.  Their basic profile is 
outlined in the table below: 
 
Total patients in study 68 
Male 54 
Female 14 
Age range 33-79 
Mean age 63 
CABG alone 51 
Aortic valve replacement alone 9 
Aortic valve replacement plus CABG 6 
Mitral valve repair/replacement 2 
 
Table 3.1 – profile of patients recruited into atrial appendage studies 
 
Explantation and transport of right atrial appendages 
During right-heart cannulation for the establishment of cardiopulmonary 
bypass, right atrial appendages were surgically excised.  This was 
performed by the application of a haemostatic purse-string suture around the 
base of the atrial appendage, after which either scissors or a scalpel blade 
was used to remove the tissue.  Using forceps it was gently placed into a 
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plastic tube containing 50ml modified Tyrode‟s buffer at 4°C.  This was 
sealed, labeled and transported on ice to the laboratory.  The buffer had 
been preoxygenated with 95% O2/5% CO2, achieving a PO2 between 50 and 
60 kPa and a PCO2 of between 4 and 6 kPa. The pH of the transport buffer 
was checked to ensure it was between 7.35 and 7.45.  The temperature 
remained below 4°C during transport.  Transport time was <10 minutes in all 
cases. 
 
Dissection, explantation and stabilisation of human atrial 
trabeculae 
In the laboratory, the entire atrial appendage was secured in a dissection 
dish using pins, whilst still immersed in cold buffer.  The appendage was 
gently opened to expose the endocardial surface, and individual atrial 
trabeculae were gently dissected and excised.  They were then explanted 
into individual 25 ml organ baths equipped with pacemaker electrodes, on a 
custom-built superfusion rig (Radnoti Glass Technologies, USA).  5/0 silk 
sutures were used to secure one end of the trabeculae to a fixed glass hook, 
and the other to a force transducer.  Five separate superfusion baths were 
available per experiment.  Once mounted, the trabeculae were superfused 
with modified Tyrode‟s buffer comprising (in mmol/L) 118.5 NaCl, 4.8 KCl, 
24.8 NaHCO3, 1.2 KH2PO4, 1.44 MgSO4.7H20, 1.8 CaCl2.2H2O, 10.0 
glucose and 10.0 sodium pyruvate. The solution was oxygenated with a 
95%O2/5%CO2 mixture.  pH was maintained between 7.35 and 7.45 with a 
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partial pressure of O2 between 50 and 65 kPa and a partial pressure of CO2 
between 4.0 and 6.0 kPa.  Buffer which had passed through the superfusion 
baths was recirculated using a peristaltic pump (5056, Watson-Marlow, UK).  
A constant temperature of 37° was maintained using a circulating water 
jacket and heat exchanger (Thermo Electron Corporation, USA), and this 
was regularly checked using a calibrated electronic thermometer throughout 
the experiment. Buffer pH, ppO2, ppCO2 and glucose levels were measured 
at predetermined points during the experiment by sampling fluid direct from 
the superfusion baths, and using an automated blood-gas analyser (ABL 700 
series, Radiometer Limited, UK).   
The atrial trabeculae were paced at 1 Hz using a dual pulse stimulator via 
the platinum electrodes in the superfusion baths (Harvard 6012 stimulator, 
Harvard Apparatus, UK).  The stimulators were all set to deliver a fixed, 
continuous signal with a width of 2ms and an output of 30V.  Once set up in 
this fashion, the trabeculae were allowed to stabilise for 75 minutes.  
Trabecular tension and force of contraction was amplified, monitored and 
recorded with a Powerlab/8sp instrument (AD Instruments, Australia).  Peak 
contractile function at the end of the stabilisation phase was recorded and 
provided a baseline for comparison later.  
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Fig 3.1 – human right atrial appendage during dissection, with trabecular 
sutures positioned immediately prior to explantation. 
 
 
Fig 3.2 - computer screen showing transduced contractile activity from 5 
human atrial trabeculae receiving 1Hz pacing stimulus during stabilisation 
phase. 
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Exclusion criteria 
Trabeculae were excluded as follows: 
1. If, on measurement, they were >1.2mm in diameter or <2mm in length. 
2. If they were mechanically damaged during dissection or mounting (as 
assessed visually). 
3. If time to explant took >20 minutes. 
4. If the contractile force failed to reach 0.5g after 75 minutes of stabilisation, 
or; 
5. If any evidence of electro-mechanical instability during stabilisation 
 
Simulated ischaemia-reperfusion injury 
Following stabilisation, atrial trabeculae were then subjected to a period of 
hypoxia which comprised 90 minutes of superfusion with glucose-free 
hypoxic modified Tyrode‟s buffer composed of (in mmol/L) 118.5  NaCl, 4.8 
KCl, 24.8 NaHCO3, 1.2 KH2PO4, 1.44 MgSO4.7H20, 1.8 CaCl2.2H2O, 7.0 
choline chloride.  Pacing was increased to 3Hz.  The buffer had been 
previously bubbled with 95%N2-5%CO2 to achieve a partial pressure of O2 to 
< 8kPa with a physiological pH.  After 120 minutes, simulated reperfusion 
followed.  To achieve this, trabeculae were superfused with the oxygenated, 
glucose-containing buffer used during the stabilisation phase, and pacing 
frequency was returned to 1 Hz.  At the end of this phase, residual 
contractile function was measured and recorded as a percentage of baseline 
function.  After the conclusion of the experimental protocol the trabeculae 
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were removed from the apparatus and the sutures were carefully removed.   
The length, width and weight of the trabeculae were measured and 
recorded. 
 
 
Fig 3.4 – human atrial trabecula in organ bath 
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Fig 3.5 – human atrial superfusion equipment showing arrangement of 
reservoirs, organ baths and pacemaker stimulators 
 
Application of experimental protocols and infusion of 
pharmacological agents 
Using the apparatus outlined above, it was possible to apply experimental 
protocols incorporating ischaemic preconditioning or pharmacological 
cardioprotection. To simulate IPC hypoxic buffer was selectively diverted to 
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the appropriate tissue bath alone for a 3 minute interval, followed by a 7 
minute restoration of stabilisation buffer immediately prior to the main 90 
minute hypoxic insult. 
 
To allow selective exposure to a range of pharmacological agents, individual 
1 litre reservoirs were housed above each tissue bath.  These could be 
operated as wholly isolated circuits via an array of separate tubing, a three-
way tap and a recirculation pump.  The effluents from the baths were 
carefully managed to ensure no cross-contamination between isolated 
circuits.  Circuits were thoroughly decontaminated after each use, an 
received acid cleaning after each main experimental phase. 
 
Trabeculae were randomly assigned to experimental protocols at the end of 
the stabilisation phase, using a computer-generated numbering system. 
 
Recovery of baseline function as an indicator of 
cardioprotective efficacy 
The force of trabecular contraction was carefully measured at the end of the 
experimental protocol, and was recorded.  This was divided by the force of 
contraction at baseline and recorded as a percentage value. 
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Critical analysis of the model 
This human atrial superfusion protocol examines and records functional 
recovery as a surrogate marker of the degree of myocardial injury sustained 
following a sustained period of glucose-free hypoxia.  It is a simulation, ex-
vivo, of the biochemical milieu encountered during an ST-elevation 
myocardial infarction, using explanted human myocardial tissue.  The model 
has been shown to provide reproducible data when using human tissue to 
assess simulated ischaemia-reperfusion injury, simulated ischaemic 
preconditioning, and using pharmacological agents to provide 
cardioprotection (64;83;269-274).  Recently it has also been used to 
examine the effects of ischaemic postconditioning (82). 
 
One potential criticism of the models surrounds the use of atrial, rather than 
ventricular tissue.  The only human tissue available to researchers in this 
field will be of atrial origin.  Ventricular tissue is rarely resected during routine 
cardiac surgery.  Ventricular wall tissue is removed only as part of a (now 
rarely-performed) aneurysectomy, in which case it is mostly non-contractile 
scar tissue.  Septal myectomy for patients with hypertrophic cardiomyopathy 
is performed (discussed below) but this results in fragments of tissue being 
excised which are not presented as functional subunits which could be 
compared.  Additionally, the underlying genotyic and phenotypic abnormality 
is present throughout the tissue removed. 
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Oxygen and substrate delivery to the cells during the experimental phase 
relies on diffusion from the surrounding buffer.  It is not possible to perfuse 
the trabeculae independently as they are too small and lack an individual 
arteriolar entry point.  To ensure that diffusion to the inner core of the tissue 
was not compromised, an exclusion cut-off diameter of 1.20mm was applied.  
This was based on the work of previous researchers using this model, and 
previous work using ventricular papillary muscles, showing a reproducible 
functional recovery using similar diameter tissue samples (64;82;83;269-
274). 
 
At the outset, it is acknowledged that all trabeculae were excised from 
patients undergoing cardiac surgery for either coronary artery disease, 
cardiac valve disease, or both.  Thus the tissue samples, at baseline, were 
not truly normal.  However the underlying diseased state was identical for all 
trabeculae isolated from an individual patient, and was similar overall for 
both intervention and control groups.  Moreover, a control arm was 
maintained within each individual experiment where multiple protocols were 
being applied, to ensure overall function and reproducibility of the model.  
The ability to have an inbuilt control arm during each experiment is a 
particular strength of this model. 
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Human myocyte isolation 
Study Subjects 
Patients undergoing elective ventricular myectomy for obstructive 
hypertrophic cardiomyopathy at the Heart Hospital, University College 
London Hospitals NHS Foundation Trust, London, were screened for 
eligibility for these studies. 
 
Prior ethical approval for the study was obtained from the University College 
London/University College London Hospital Committee on the Ethics of 
Human Research, sub-committee alpha.  Fully informed consent was 
obtained at the pre-admission visit some weeks prior to planned surgery.  
Patients were not approached for consent discussions or possible 
recruitment if they had received sedatives or opiate medication, to ensure 
consent was fully informed. 
Exclusion Criteria 
The following patients were excluded: 
1. Patients over the age of 79 years. 
2. Patient with concurrent coronary artery disease or any history of 
myocardial infarction 
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3. Patients who had undergone previous alcohol septal ablation therapy for 
HCM 
4. Patients with renal impairment (eGFR <60ml/min) 
Patient profiles 
Total patients in study 8 
Male 5 
Female 3 
Age range 28-55 
Mean age 47 
 
Table 3.2 – Profile of patients undergoing myectomy for HCM 
Tissue excision, handling and transport 
A transport buffer comprising 10ml Harefield hospital formulation high-
strength cardioplegia solution (comprising, in mmol/L, 147 Na,  84 K, 80 Mg,  
2 Ca, 5 procaine , 400 Cl) made up to 50 mls with compound sodium lactate 
intravenous solution (comprising, in mmol/L 131 Na, 5 K, 2 Ca , 111 Cl, 29 
lactate) was prepared in advance and stored at 4˚C.  Pre-operatively, there 
was close liaison with theatre staff in order to optimise handling of the 
excised tissue.  Usual practice was to request that the excised tissue be 
placed in a pot of saline prior to being handed to the researcher.  If this was 
impractical, moistened gauze was used to cover the tissue to prevent 
exposure to the air and subsequent dessication and possible cell loss. 
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Following induction of general anaesthesia, perioperative transoesophageal 
echocardiography, and after establishing cardiopulmonary bypass, the 
surgeon performed an aortotomy.  Having retracted the aortic valve, under 
direct vision and using echocardiography as a guide, the obstructive 
ventricular septal tissue was resected.  The mass of tissue removed ranged 
from 2-11 grammes. 
Following excision, approximately 0.5 to 1.0 grammes of septal tissue were 
placed into the transport buffer.  The sample was handled gently using 
DeBakey forceps.  This tube was then sealed, labelled, and placed into a 
flask of ice prior to rapid transport to a laboratory facility. 
 
 
Fig 3.5 -  Myectomy sample in transport buffer 
Tissue dissection 
The sample was placed on an inverted plastic dish and reduced to much 
smaller pieces (approximately 1mm3) by careful razor cleavage, using clean 
straight cuts over 5 minutes.  Care was taken to avoid applying shearing 
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forces to the tissue where possible, which results in a reduced myocyte 
yield, and the tissue was kept moist by liberally applying aliquots of the 
transport buffer throughout. All containers used in the processing of the 
sample were plastic, and these were carefully rinsed.  No glassware was 
used to avoid the possibility of introducing calcium contamination.  Similarly, 
all reagents used for buffer composition were Aristar™ certified, i.e. low 
calcium content. 
Once reduced in size, the tissue fragments were washed to remove debris 
and traces of the cardioplegia solution.  4 washes each of 3 minutes using 
25ml low-calcium buffer  (comprising, in mmol/L 120 NaCl,  5.4 KCl, 5 
MgSO4, 5  pyruvate , 20 glucose, 20 taurine, 10 HEPES, pH 6.96) were 
performed.  During this phase the solution containing the tissue was stirred 
manually using a handheld device, with 100% oxygen bubbling through the 
solution.  The container was immersed in a water bath to maintain a stable 
temperature, pre-heated to 35˚C.  Between washes, the wash solution was 
poured through a 300 µm nylon gauze filter and discarded, retaining only the 
tissue.  The wash cycle was continued until a total of 12 minutes incubation 
time was reached 
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Fig 3.6 -  Tissue cleavage using razor blade 
Proteinase cycle 
Following discarding the final 25ml of wash solution, the tissue fragments 
were placed in a 50ml plastic tube.  15 ml of 4U/ml bacterial type XXIV 
protease solution were added (8038-1G, Sigma Aldrich, UK).  The tube was 
then immersed in the water bath, and a tubing array delivered oxygen across 
the surface of the solution.  A flask-shaker (Stuart SF-1, Stuart Scientific) 
was used to hold the tube and agitate the solution for the next 45 minutes. 
Collagenase cycle 
The tissue suspension was poured through a fresh nylon gauze filter and 
funnel assembly, and the tissue fragments carefully placed into another 50 
ml plastic tube.  15 ml of 400IU/ml collagenase solution were added (C9263-
5G, Sigma Aldrich, UK) and the tube returned to water bath.  Again, oxygen 
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flow across the surface of the solution was maintained, and the tube was 
agitated for a further 45 minute cycle. 
 
Fig 3.7 - Oxygenated tissue fragments undergoing digestion & oxygenation 
in water bath 
Centrifugation 
Following the digestion cycles, the resulting suspension was filtered through 
a fresh 300µm nylon gauze filter, and the resulting filtrate collected in a 
plastic test tube.  This was then centrifuged gently at 400 revolutions per 
minute for 1 minute.  This resulted in the formation of a pellet of myocytes at 
the bottom of the tube.  The supernatant was gently removed using a plastic 
pipette, and a further 5-10 ml of enzyme carrier solution (minus enzyme) was 
added to resuspend the myocytes.  The centrifugation cycle was repeated, 
and the resulting supernatant discarded.  This cycle served to further clean 
the filtrate.  Finally, the pellet was resuspended and 2 ml of the enzyme 
solution.  A drop of this suspension was examined using light microscopy to 
confirm the presence of myocytes.  The myocyte suspension was transferred 
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into a fresh plastic tube, and topped up to avoid bubble formation, to avoid 
causing mechanical damage to cells during transit.  The tube was also 
transported lying horizontally to prevent the myocytes from clumping, and 
potentially forming a hypoxic nidus in the middle of the clump. 
 
Myocyte preparation 
Krebs-Henseleit solution had been previously prepared (comprising, in 
mmol/L NaCl 118, KCl 4.7, NaHCO3 25, MgSO4 1.22, KH2PO4 1.21, Ca
2+  
1.84, glucose 11) to which HEPES 1M was added at a ratio of 1% per unit 
volume of buffer. 
The tube containing the myocyte suspension was kept at room temperature 
and placed on a gyratory rocking platform (SSM3, Stuart) to gently prevent 
cell clumping without causing mechanical injury. 250 µL of the solution was 
now removed by micropipette, using a gentle action to further reduce 
damage, and carefully placed onto a 25mm diameter round coverslip.  250 
µL of the Krebs/HEPES buffer was then gently added over 30 seconds.  This 
served to gradually raise the ambient calcium concentration in the resulting 
solution.  The slow addition was aimed at avoid sudden calcium flux which 
results in cell swelling and death. 
This process has been extensively used for human myocyte isolation, and 
represents a robust and reproducible process for extracting viable human 
cells (64;275). 
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Fluorescent cationic dye loading 
5 µL of tetramethyl rhodamine methyl ester (TMRM) 3 µM was added to the 
solution, and incubated at room temperature for 15 minutes.  TMRM is a 
monovalent cationic fluorescent dye, which selectively accumulates within 
the mitochondrial membrane.  The loaded coverslip wells were shielded from 
light during the incubation phase. 
 
 
 
Fig 3.8 -   Left-hand panel - isolated human cardiomyocte under light 
microscopy. Right-hand panel – the same cell viewed with confocal 
microscopy following loading with the cationic dye TMRM. 
 
Drug treatment 
In the groups randomised to receive drugs, the agents were added via 
micropipette 5 minutes after addition of TMRM, and allowed to incubate for a 
further 10 minutes.  The total incubation time with TMRM present did not 
exceed 15 minutes.  Control groups of cells received DMSO alone at this 
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point.  In the group randomised to receive atorvastatin, 2.5 µL of 5 mM stock 
was added by micropipette to give a final concentration of 25 µM.  In the 
ciclosporin-A group, 0.5 µL of 0.2 mM stock was added, resulting in a final 
concentration of 0.2 µM.  These drug concentrations have previously been 
shown to be cardioprotective in animal models, ex-vivo isolated myocardial 
models, and isolated cellular models. 
 
Confocal microscopy 
The  chamber containing TMRM-loaded myocytes and drug/carrier was 
mounted on the viewing stage of a confocal microscope (TCS SP5, Leica 
Microsystems GmbH, Germany), and cells were examined using a ×20 
quartz objective lens.  A 543-nm emission line from a HeNe laser at 20% 
power was used to illuminate the cells, using a sector sweep speed of 5.2 
seconds.  Comparability between different experiments was ensured by 
maintaining  identical conditions with respect to laser power, confocal 
pinhole, and optical slice and detector settings.  TMRM fluorescence was 
acquired via a 585nm filter, and the images were analysed using Leica 
software (Leica Application Suite, Advanced Fluorescence, Leica 
Microsystems GmbH, Germany).  
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Fig 3.9 -  Confocal microscope system 
 
Exclusion criteria 
Myocytes were selected  that were as morphologically normal as possible.  
Specifically, cells were excluded in the following circumstances: 
 
1. Cells with >30% fibrillar disarray or where architecture unclear 
2. Cells with multiple promontories 
3. Cells which show evidence of partial depolarisation at start of imaging 
4. Cells <60nm in length or <30nm wide 
5. Cell batches >2 hours from completion of isolation 
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Laser Oxidative Stress  
Once a suitable cell was identified, laser photosensitization was 
commenced.   The high concentration of TMRM within the mitochondria 
effectively focuses the oxidative stress within the mitochondria. This 
eventually causes global loss of mitochondrial membrane potential, 
signifying opening of the mitochondrial permeability transition pore.  As this 
occurs, TMRM is released into the cytosol, and an increase in signal can be 
detected. The opening of the mPTP has been previously demonstrated to be 
a critical determinant of cell death in a variety of animal models of 
ischaemia-reperfusion injury (27;51;52;56;276-280), and in isolated human 
atrial myocytes (64). 
End Points 
The time taken to the onset of mitochondrial depolarisation was recorded.  
The two preselected experiment end-points were either the establishment of 
a clear forward wave of depolarisation, or regional, progressive loss of 
subcellular structure.  
It was possible to perform experiments on up to three groups of cells per 
isolation.  After three groups (and especially after two hours post-isolation), 
live cell yield started to decline significantly, and further experiments were 
not pursued after this time.   
The mean depolarisation time for each group was then normalised against 
the control group. 
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Fig 3.10 - Human ventricular myocyte under confocal microscopy, showing 
progressive wave of depolarisation signifying mPTP opening. 
 
Critical Analysis of the Model 
The laser oxidative stress model described uses a standardised laser insult 
to induce loss of mitochondrial membrane potential in human ventricular 
myocytes.  The end point used is a precursor to cell death, rather than cell 
death itself.  However, this model has produced robust and highly 
reproducible data in published studies using both animal and human atrial 
myocardial cells. 
 
A particular strength of the model is that it allows analysis of freshly excised 
human ventricular cardiomyocytes.  Studies of cellular mechanisms of 
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cardioprotection in human tissue are frequently limited to investigation of 
atrial tissue, which is more readily available.  
 
Clearly, these investigations are limited to single-cell experiments, and do 
not necessarily reflect the behaviour of a whole, perfused piece of tissue or 
organ.  Additionally, our studies were necessarily confined to the 
investigation of patients with hypertrophic cardiomyopathy.  Ventricular 
tissue excision is effectively limited to surgery for this condition, in which 
tissue debulking is the surgical therapeutic aim.  However this allows for 
specific investigation of cardioprotective mechanisms in the setting of this 
condition. 
 
The cell isolation process is time consuming, and during this period cells are 
lost.  Additionally, during the transport phase between isolation and confocal 
laser laboratories, further cell loss was noted.  A finite time period of two 
hours from the end of isolation phase was imposed, limiting the numbers of 
experiments that could be performed 
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Chapter Four:  ATORVASTATIN ADMINSITERED AT 
REPERFUSION PROTECTS HUMAN ATRIAL MYOCARDIUM 
AGAINST SIMULATED ISCHAEMIA-REPERFUSION INJURY 
THROUGH ACTIVATION OF THE RISK PATHWAY AND 
NITRIC OXIDE SYNTHASE 
 
 
Introduction 
Emergency reperfusion of an occluded coronary artery by means of 
percutaneous coronary intervention (PCI) limits infarct size, and reduces 
mortality and recurrent cardiac event rates (21;22) .  Where PCI is 
unavailable, thrombolytic therapy remains an option for achieving 
reperfusion, albeit with a lower success rate (23;281;282). 
 
Even after rapid reperfusion, further cardiomyocyte loss in the infarct territory 
occurs, believed to be caused by a combination of both necrosis and 
apoptosis (36;37;283).  This represents lethal reperfusion injury, and may 
contribute to the burden of morbidity or mortality seen even after successful 
reperfusion therapy.   
 
HMG Co-A reductase inhibitors (statins) have a proven and established role 
in the primary and secondary prevention of cardiovascular disease in 
humans.  They are effective in reducing serum levels of low density 
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lipoprotein cholesterol, and have been shown to reduce rates of myocardial 
infarction and cardiovascular death in both these settings, and lead to 
regression of coronary atherosclerotic lesions.  (87;89-91) 
 
Experimental animal models have demonstrated that acute therapy with 
statins reduces infarct size independently of its effect on serum lipids (72).  
This effect is present whether  initiation of statin therapy precedes infarction 
by a few days (104), is given at the point of reperfusion (72) following a 
severe ischaemic insult, or is administered enterally within 3 hours of 
myocardial infarction.  The cardioprotective effect has been demonstrated 
most recently with simvastatin, atorvastatin and rosuvastatin (109). 
Additionally, in an animal model of ischaemia-reperfusion injury, upstream 
treatment with atorvastatin (as a preconditioning mimetic) has been shown to 
be cardioprotective and lead to a reduction in final infarct size (284) . 
 
Acute statin therapy modulates ischaemia-reperfusion injury in both cellular 
and animal models, by pharmacological activation of the pro-survival PI3K-
Akt and Erk-1/2 signalling cascades during the reperfusion phase (72;285).  
This cascade has been named the Reperfusion Injury Salvage Kinase 
(RISK) pathway (286;287).  Pharmacological inhibition of PI3-K, abrogates 
this cardioprotective effect (72). 
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The proven beneficial cardiovascular effects of statins in humans have 
recently been extended to include administration to patients suffering from 
acute coronary syndromes undergoing urgent PCI (190), those undergoing 
cardiac surgery (170;288),  and prior to major vascular non-cardiac surgery 
(289).  Whether these benefits are derived primarily from a reduction in 
myocardial ischaemia-reperfusion injury or are related to a range of other 
pleiotropic effects is unclear.  These actions include the stabilisation of 
unstable coronary atherosclerotic plaques, improved endothelial function, 
and reduced adhesion molecule expression. (96-98).  There is currently no 
evidence regarding the ability of stain therapy to ameliorate the effects of IRI 
in human myocardial tissue, and less is known about the signaling pathways 
involved in human patients. 
Hypothesis 
Atorvastatin is cardioprotective in human myocardium, acting by the 
activation of prosurvival signalling pathways including the RISK enzymes 
and nitric oxide synthase isoforms. 
 
Objective 
The objective was to determine the role of atorvastatin with respect to 
potential acute cardioprotection of human myocardium following ischaemia-
reperfusion injury.  In experimental settings, cardioprotection derived from 
statins following ischaemia-reperfusion injury has been shown to be linked to 
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the activation of enzymes in the prosurvival RISK pathway (72;285;290), but 
the applicability of this mechanism in human myocardium has not been 
established.  Additionally, statin-induced cardioprotection seen in animal 
models is also closely linked with up-regulation of nitric oxide synthase 
isoforms (103;107;291;292).  It was intended to additionally examine the role 
of nitric oxide synthase in statin-induced cardioprotection in humans.  
 
Materials & methods   
Atorvastatin was supplied by Pfizer Incorporated, USA.  It was dissolved in 
dimethyl sulphoxide (DMSO) and added to the Tyrode‟s reperfusion buffer at 
a concentration of 25 µM.  The PI3-kinase inhibitor LY294002 (2-(4-
morpholinyl)-8-phenyl-4H-1-benzopyran-4-one hydrochloride, Sigma-Aldrich, 
Poole, UK) was dissolved in DMSO and added to the buffer at a 
concentration of  15µM.  The p42/44 MAP kinase inhibitor, UO126 (Sigma-
Aldrich), was dissolved in DMSO and added to buffer to give a concentration 
of 10 µM.  The nitric oxide synthase inhibitor, L-NAME (Nitro-L-arginine 
methyl ester hydrochloride, Sigma-Aldrich)) was added directly to the 
reperfusion buffer at a concentration of 100µM.  1400W (N-([3-
(Aminomethyl)phenyl]methyl)ethanimidamide dihydrochloride, Sigma-
Aldrich), a specific inhibitor of inducible nitric oxide synthase, was dissolved 
directly into Tyrode‟s buffer giving a final concentration of 5 µM.  The final 
concentration of DMSO used, where applicable, was <0.01%.  The 
experimental methods have been outlined in chapter 3. 
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Pilot studies 
To determine a suitable concentration of atorvastatin to use in this 
experimental setting, a series of experiments was performed to resolve 
technical issues.  Since atorvastatin is highly insoluble and will not dissolve 
directly into aqueous buffer at the temperatures used in this experimental 
protocol, a suitable carrier solvent was required to allow the drug to be 
added to the superfusate buffer (see below). 
 
A total of 10 trabeculae, isolated from 4 patients, were exposed to 
atorvastatin dissolved in varying concentrations, initially using methanol as 
solvent.  Recovery of function in this group was below that of 
contemporaneous controls, suggesting either no effect from the atorvastatin, 
or possibly even a directly toxic effect attributable to either drug or solvent 
(see Fig 4.1 below).  In an attempt to rectify this, the carrier agent was then 
changed from methanol to DMSO. Atorvastatin 25 µM dissolved in DMSO as 
a carrier solvent established enhanced recovery of function suggesting 
cardioprotection was occurring , and  this concentration was used for 
subsequent experiments.  The presence of DMSO alone in the superfusion 
buffer was investigated and had no protective effect on functional recovery, 
in keeping with previous data using this experimental model (64;82;83;269-
274).  Methanol was not subsequently used as a carrier solvent. 
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.  
Fig 4.1 - Functional recovery of trabeculae during pilot phase using methanol 
then DMSO as carrier for atorvastatin 
 
Study subjects 
31 patients were consented for these experiments and had their results 
analysed and included.  A further 9 patients consented, but the tissue 
samples were either too small for atrial trabeculae to be isolated, or they 
were damaged during the explantation process.  The mean number of 
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trabeculae per patients was 2.3. The following table outlines the profile of 
surgical patients included in this study 
 
Total patients in study 31 
Male 25 
Female 6 
Age range 50-79 
Mean age 64 
CABG alone 23 
Aortic valve replacement alone 4 
Aortic valve replacement plus CABG 3 
Mitral valve repair/replacement 1 
 
Table 4.1 – Subjects recruited for atorvastatin studies 
 
Experimental protocol 
Explanted human atrial trabeculae were randomly assigned to one of the 
following treatment groups:   
 
(1) Control group (n=17) – no additional agent during reoxygenation phase. 
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(2) Hypoxic preconditioning (n=4) – a standard hypoxic preconditioning 
(HPC) protocol was used as a positive control group.  This allowed 
comparison with a preconditioning protocol consisting of 3 minutes 
superfusion with hypoxic glucose-free buffer and pacing at 3 Hz followed by 
7 minutes of superfusion with oxygenated glucose-containing buffer and 
pacing at 1 Hz, immediately prior to the 90 minute hypoxic phase. HPC is 
well established in inducing resistance to HRI in this experimental model. 
(64;82;83;269-274) 
 
(3) ATV (25µM) (n=9).  A dose in the mid therapeutic range was selected 
based on preliminary investigations and preclinical animal cardioprotection 
studies (72).  ATV was administered at the point of reoxygenation and 
throughout the 120 minute reoxygenation period. 
 
(4) ATV with the P42/44 MAPK-kinase inhibitor LY294002 (15µM), both 
drugs administered at and throughout reoxygenation (n=4). 
 
(5) ATV with the PI3-kinase inhibitor UO126 (10µM), both drugs 
administered at and throughout reoxygenation (n=4). 
 
(6) ATV with the nitric oxide synthase inhibitor L-NAME (100µM), both drugs 
administered at and throughout reoxygenation (n=7). 
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(7) ATV with specific inducible nitric oxide synthase inhibitor 1400W (5µM)), 
both drugs administered at and throughout reoxygenation (n=5). 
 
(8) ATV with DMSO vehicle control (n=4). 
 
(9) Inhibitor-only control with LY294002 (15µM), control tissue with drug 
administered at and throughout reoxygenation (n=5). 
 
(10) Inhibitor-only control with UO126 (10µM), control tissue with drug 
administered at and throughout reoxygenation (n=4). 
 
(11) Inhibitor-only control with L-NAME (100µM), control tissue with drug 
administered at and throughout reoxygenation (n=5). 
 
(12) Inhibitor-only control with 1400W (5µM), control tissue with drug 
administered at and throughout reoxygenation (n=5).
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Groups 4-7
Atorvastatin 25µM
plus inhibitors
90 min
hypoxia
120 min
reoxygenation
75 min
stabilisation
Group 1
Control
Group 8
Atorvastatin 25µM
plus DMSO 
Groups 9-12
Control with inhibitors
Group 2
Hypoxic preconditioning
Group 3
Atorvastatin 25µM
Inhibitors
Inhibitors
DMSO
 
Fig 4.2 – Experimental protocol for atorvastatin studies 
 
Results 
Right atrial appendages were obtained from 31 patients with stable 
CAD/valve disease.  A total of 71 trabeculae met inclusion criteria and were 
randomised into the treatment groups outlined above.  Mean baseline 
contractility in the control group was 0.93+/-0.08g, which compares 
favourably with 0.92+/-0.1g in the arm randomised to receive atorvastatin at 
reperfusion.   
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Atrial trabeculae in the control group recovered 37.05±1.33 % of baseline 
function contractile function.  This is in keeping with previous studies using 
the same model (64;82;83;269-274). Atorvastatin 25 µM markedly improved 
the recovery of contractile function to 61.0±2.3 %, an improvement which 
was highly statistically significant (p<0.001) when compared against the 
control group. This improvement in recovery of contractile function was of a 
similar magnitude to that achieved in the group of trabeculae exposed to 
hypoxic preconditioning (60.4 ± 3.8%). 
 
 
Fig 4.3 – Functional recovery of atrial trabeculae treated with atorvastatin 
compared to positive control with hypoxic preconditioning stimulus 
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The improvement seen with ATV 25 was abolished by the co-administration 
of LY294002 (the PI3-kinase inhibitor), UO126 (the p42/44 MAP kinase 
inhibitor), L-NAME (a non specific nitric oxide synthase (NOS) inhibitor) and 
1400W (a specific inducible NOS inhibitor).   
 
 
 
Fig 4.4 – Functional recovery data with atorvastatin plus inhibitor agents 
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The inhibitor agents alone, or DMSO carrier alone, had no effect on 
functional recovery, as shown below.  Trabeculae in these groups recovered 
function as follows:  LY 34.01±2.72%, UO126 35.12±4.90 %, L-NAME 
30.59±3.33%, 1400W 29.62±2.05, and 35.20±2.98% in the DMSO carrier-
control group.  These values compare favourably with the control group, in 
which recovery was 37.05±1.33 % of baseline function contractile function, 
and are shown below. 
 
 
Figure 4.5 – functional recovery data using carrier or inhibitor-only controls 
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Diabetic subgroup analysis 
Diabetic patients are at higher risk of developing cardiovascular disease than 
nondiabetic patients (293), with more than double the background population 
risk of myocardial infarction (294;295) .  Once cardiovascular disease has 
become established, patients with diabetes have higher morbidity and 
mortality (296). Protection of the diabetic myocardium has received 
considerable experimental attention, but has been shown to be more difficult 
to achieve than in non-diabetic states. Some studies have suggested that 
traditional preconditioning techniques may fail to work altogether when 
applied in the setting of diabetes (229;297-299), possibly due to 
mitochondrial K-ATP channel dysfunction (300).  Animal studies have 
confirmed that, if preconditioning is to be achieved, a higher intensity 
preconditioning stimulus must be applied  when compared to non-diabetics 
(301), possibly due to impaired PI3K/Akt signalling (302;303) . Studies by 
our group using human atrial trabeculae support the concept that diabetic 
tissue can be successfully preconditioned, but a stronger stimulus was 
required (304;305). It appears that in the setting of diabetes, the threshold 
for cardioprotection is raised. 
To investigate these findings, and to establish whether pharmacological 
cardioprotection is possible in the setting of diabetes, a direct comparison 
between diabetic tissue receiving atorvastatin treatment versus non-diabetic 
tissue was also performed. 
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Due to the randomisation process, the number of trabeculae in this analysis 
is small.  Mean recovery of function in tissue from diabetics was 
35.31±0.83% (n=4), compared with 37.59±1.71% in nondiabetics (n=13).  A 
functional recovery value of 61.14±3.0% was obtained in non-diabetic 
trabeculae treated with atorvastatin (n=7), compared with 60.74±2.97% in 
treated diabetic tissue (n=2).  It is accepted that these values are small, but 
the initial suggestion is that the cardioprotective effect is present irrespective 
of underlying diabetes mellitus. 
 
 
Fig 4.6 – Functional recovery in diabetic subgroup 
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Discussion 
The major findings in this study are: (a) human atrial myocardium can be 
protected from simulated ischaemia reperfusion injury by treatment with 
atorvastatin 25 µM administered concurrent with reperfusion and (b) the 
protection offered by atorvastatin administration is abolished by the presence 
of PI3K inhibitors, Erk-1/2 inhibitors, and nonspecific NOS and specific 
inducible NOS inhibitors.  This implicates a role for the RISK pathway and 
NOS in the mediation of atorvastatin-induced cardioprotection in humans.   
 
Statin-induced cardioprotection has been described and characterised in 
isolated perfused murine (72;306) and rat hearts (180;284;307), and in-vivo 
in the mouse and rat (103-106;291;292).  Perhaps the most consistent 
finding from the animal experimental data is the role of activation of the RISK 
pathway and NOS signalling systems (72;106;291).  Activation of the PI3K 
and Erk-1/2 protein kinases at the time of myocardial reperfusion has been 
shown to confer powerful cardioprotection(286).    The mechanism through 
which statin therapy may directly activate the RISK pathway is not clearly 
defined, but canine work suggests it involves the potentiation of myocardial 
adenosine by ecto-5‟-nucleotidase (308).   
Statin-mediated cardioprotection is also thought to be mediated by a direct 
increase in eNOS protein expression as a result of stabilising eNOS mRNA 
(309-311). Furthermore, statin cardioprotection cannot be elicited in the 
absence of eNOS, as evidenced by the lack of statin effect in eNOS-deficient 
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animal models (72;312)   Studies have also suggested that eNOS 
phosphorylation by the PI3K and Akt signalling cascades may be 
responsible for an increase in protective eNOS activity(313).   The 
importance of these systems in human myocardial tissue is supported by the 
findings above, in that inhibition of components of the RISK pathway and 
NOS signalling pathways were shown to abolish cardioprotection.   
For the first time this data confirms that atorvastatin elicits its 
cardioprotection in humans through a direct myocardial effect involving 
prosurvival signalling pathways.  
 
In this study, atorvastatin has been shown to protect the myocardium when 
administered at the time of reoxygenation, and this could be of clinical 
benefit in the setting of acute coronary syndromes especially ST-elevation 
myocardial infarction.  Additionally, in situations where myocardial ischaemia 
can be predicted, pretreatment with atorvastatin could be a clinically useful 
tool with which to reduce myocardial injury.  These settings could include 
elective cardiac surgery or percutaneous coronary interventions. Both 
procedures have been shown to be associated with myocardial injury as an 
unwanted side effect of the therapeutic intervention, as evidenced by 
biomarker release and magnetic resonance imaging data (122;268), and in 
both settings are associated with adverse clinical outcomes.  Following PCI, 
unwanted biomarker release (indicating myocardial necrosis) occurs in 5-
30% of cases (314), influenced by technical aspects of the procedure 
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difficulty, and the degree of  pharmacological optimisation used upstream of 
the procedure (99).  Clinical studies have demonstrated that statins 
(102;315;316), and in particular high-dose atorvastatin, can ameliorate this 
myocardial damage and drive down periprocedural event rates 
(100;101;190), and the experimental findings outlined above could form part 
of the basis for these clinical effects.  The potential for this effect to extend to 
the high-risk diabetic population is an additional benefit, but further 
experimental data are required due to the low numbers in our study. 
Conclusion 
This study demonstrates, for the first time, that atorvastatin can protect 
human atrial myocardium ex vivo against simulated ischaemia-reperfusion 
injury, as evidenced by a marked improvement in recovery of contractile 
function.  This cardioprotective effect has been shown to be mediated by 
pharmacological activation of the RISK pathway and NOS.  The ability of 
atorvastatin to acutely activate this prosurvival mechanism provides a 
potential means to enhance myocardial salvage in the clinical setting of 
acute coronary syndrome patients undergoing emergency reperfusion 
therapy.
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Chapter Five: HIGH-DOSE PREOPERATIVE 
ATORVASTATIN TREATMENT OF PATIENTS 
UNDERGOING CARDIAC SURGERY RECAPTURES 
PROTECTION OF ATRIAL MYOCARDIUM AGAINST 
SIMULATED ISCHAEMIA-REPERFUSION INJURY 
 
Introduction 
 
Since its introduction in 1968, coronary artery bypass grafting (CABG) 
became established as the standard of care for patients suffering from multi-
vessel coronary artery disease (117).  Vascular conduits are used to bypass 
diseased major epicardial blood vessels to improve survival, reduce angina, 
and preserve function of the left ventricle.  The conduits used are most 
commonly the left internal mammary artery onto the left anterior descending 
artery, and saphenous vein grafts onto the circumflex and right coronary 
artery territories.  More complete revascularisation using bilateral internal 
mammary artery grafts may improve survival outcomes (125) and is 
technically feasible (126), but uptake of the technique amongst cardiac 
surgeons is slow (127).      
Even with recent advances in minimally invasive percutaneous coronary 
techniques, CABG holds its place as the treatment of choice for some 
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patient groups (6).  Around 23,000 CABG procedures are performed 
annually in the UK (118) 
 
Degenerative disease affecting the aortic and mitral valves is also treated by 
cardiac surgery (118).  Surgical intervention in this setting prolongs life and 
reduces distressing symptoms. Valve disease and coronary artery disease 
frequently co-exist, mandating a combined procedure to repair or replace the 
affected valve alongside CABG surgery.  Percutaneous treatments for aortic 
and mitral valve lesions are only currently available in a small number of 
centres.   
 
The combined physical, physiological and biochemical insults faced by 
cardiac surgical patients in the perioperative phase translate into adverse 
clinical events. As well as general systemic insults including exposure to 
cardiopulmonary bypass, direct cardiac manifestations include coronary 
atheroembolic events and direct myocardial injury from handling or over-
distension.  A recent international prospective observational study confirms 
that composite morbidity and mortality in CABG patients ranges from 12-
24% (120).  A degree of myocardial necrosis is ubiquitous following cardiac 
surgery.  The extent of this can be quantified by measuring cardiac-specific 
markers such as troponins and myocardial-bound creatine kinase (CK-MB).  
Recent clinical research has shown that perioperative release of cardiac 
biomarkers is associated with poorer short and long-term outcomes (121). 
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Additionally, MRI studies confirm that detectable myocardial scar is seen 
following 32% of myocardial revascularisation procedures, with a mean 
infarct mass of 5g.  This is associated with a marked increase in adverse 
events in this cohort (122) .  Even with relatively non-invasive PCI, 
periprocedural myocardial necrosis occurs in 5-30% of cases (314), 
influenced by technical aspects of the procedure, and the degree of  
pharmacological pre-optimisation employed (99). 
 
A number of techniques have been developed which could potentially 
combat perioperative myocardial injury caused by ischaemia-reperfusion 
injury.  Work in this field has included direct comparisons of varying 
cardioplegia regimens, use of off-pump cardiac surgery 
(136;137;141;317;318), the use of external preconditioning stimuli, such as 
remote ischaemic preconditioning to activate prosurvival signalling, and the 
use of pharmacological agents such as statins (138;151;319-322).  It is this 
last approach which is investigated here. 
 
The use of statin medications as an adjunct to perioperative care has been 
examined in the settings of elective cardiac surgery (164-
166;168;170;171;321), and has been shown to exert substantial benefit on 
early postoperative adverse outcomes (174).  Statins have also been 
demonstrated to reduce periprocedural injury in patients undergoing elective 
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PCI (98;100;316) and PCI for acute coronary syndromes (101;190),  and in 
high-risk cohorts undergoing elective major vascular surgery (289) 
 
Acutely, as discussed previously (see Chapter 1), statins have been shown 
to offer cardioprotection when administered prior to an experimental 
myocardial ischaemia-reperfusion insult (104;284) , and when given during 
the reperfusion phase (72), an effect independent of their lipid-lowering 
effects .  These cardioprotective effects are mediated by activation of the 
pro-survival PI3K-Akt and Erk-1/2 signalling cascades during the reperfusion 
phase – termed the Reperfusion Injury Salvage Kinase (RISK) pathway 
(72;109;285-287) 
 
Most patients undergoing cardiac surgery are taking chronic statin therapy, 
in accordance with European guidelines for secondary prevention (162).  
With chronic statin therapy, intrinsic cellular mechanisms down-regulate 
PI3K-Akt activation and lead to loss of protection against ischaemia-
reperfusion injury – thought to be due to the effect of phosphatase and 
homolog deletion on chromosome ten (PTEN) (189) – a regulator of PI3K 
activity.  In an animal model, following a demonstrable loss of protecting 
after 1-2 weeks of statin therapy, cardioprotection was recaptured by giving 
a high supplementary dose of atorvastatin prior to an ischaemia-reperfusion 
insult (180). 
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The ability or otherwise of an acute additional administration of statin to 
recapture resistance to myocardial ischaemia-reperfusion injury in humans is 
unproven.  If present, it could suggest re-activation of the RISK pathway as a 
potential mechanism underpinning the ability of atorvastatin therapy to 
reduce periprocedural myocardial injury, and could contribute to the 
development of pharmacological strategies to reduce ischaemia-reperfusion 
injury associated with cardiac surgery or PCI. 
 
Hypothesis 
High-dose oral atorvastatin pre-treatment of patients undergoing cardiac 
surgery protects the human myocardium ex-vivo from simulated ischaemia-
reperfusion injury by activation of the RISK pathway and NOS isoforms. 
 
Study subjects 
37 patients were consented for these experiments and had their results 
analysed.  A further 9 patients consented, but the tissue samples were either 
too small for atrial trabeculae to be isolated, or they were damaged during 
the explantation process.  85 trabeculae were isolated and met the inclusion 
criteria outlined in Chapter 3.  The mean number of trabeculae included per 
patient was 2.30.  The following table outlines a profile of surgical patients 
included: 
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Total patients in study 37 
Male 29 
Female 7 
Age range 33-77 
Mean age 61 
CABG alone 28 
Aortic valve replacement alone 5 
Aortic valve replacement plus CABG 3 
Mitral valve repair/replacement 1 
 
Table 5.1 – Outline of subjects consenting to studies of atorvastatin re-
loading  
  
Materials & methods 
Atorvastatin was supplied by Pfizer Incorporated, USA.  It was prescribed 
and administered at a dose of 160mg taken 10-12 hours prior to planned 
cardiac surgery.  Enzyme inhibitors LY294002, UO126, L-NAME and 1400W 
were supplied and prepared as outlined above.  The experimental methods 
have been outlined in chapter 3.   
 
127 
 
Objective 
To investigate whether a high-dose preoperative treatment with atorvastatin 
in human subjects taking chronic background statin therapy confers 
cardioprotection on atrial trabeculae, and to establish whether 
pharmacologically inhibiting the PI3-K-Akt, Erk-1/2 pathways abolishes any 
cardioprotective effect.  Additionally, it was intended to pharmacologically 
inhibit eNOS and iNOS, as likely downstream effectors of statin-induced 
cardioprotection. 
 
Experimental protocol 
Patients were randomly assigned, using sealed envelopes, into a control 
group or a group receiving high-dose pre-treatment with atorvastatin.  Once 
they had been prepared and isolated, human atrial trabeculae were assigned 
to one of the following treatment groups. Control group trabeculae were 
randomly assigned to groups 1 or 3.  Trabeculae exposed to atorvastatin 
pre-treatment were randomly assigned to experiments with or without 
pharmacological inhibitors, into groups 2, 4 or 5.   
 
(1) Control group (n=27): Patients taking background statin therapy only (>4 
weeks prior to surgery).  
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(2) High-dose atorvastatin pre-treatment (n=22):  Patients received 160mg 
atorvastatin 10-12 hours prior to surgery on the background of chronic statin 
therapy (>4 weeks prior to surgery). 
 
(3) Hypoxic preconditioning (n=12): Atrial trabeculae from patients in a 
control group (background chronic statin therapy only) which received a 
standard hypoxic preconditioning stimulus.  This comprised 3 minutes of 
increased pacemaker frequency (3Hz) plus superfusion with glucose-free 
hypoxic buffer, followed by 7 minutes baseline pacemaker frequency (1Hz) 
plus superfusion with glucose-containing, oxygenated stabilisation buffer 
immediately prior to the main hypoxic episode.  This preconditioning group 
was included as a positive cardioprotection control.  This hypoxic 
preconditioning protocol has been previously documented to improve the 
recovery of baseline contractile function in this experimental model 
(82;83;270-274;305) 
 
(4) High-dose atorvastatin plus LY, UO, L-NAME or 1400W (n=19):  pre-
treated atrial trabeculae exposed to the following agents during the 
reperfusion phase; LY294002 , a PI3-kinase inhibitor,15 µM (n=4);  UO126, 
an Erk-1/2 inhibitor, 10µM (n=5); L-NAME, a non specific NOS inhibitor, 
100µM, (n=5); and 1400W , a specific inducible NOS inhibitor,  5 µM, (n=5).   
 
129 
 
(5) High-dose atorvastatin plus DMSO (n=5): pre-treated atrial trabeculae 
exposed only to the carrier agent DMSO (<0.01% per unit buffer volume) 
during the reoxygenation phase. 
 
Group 1
Control 
Background statins
Group 2
High-dose atorvastatin
90 min
hypoxia
120 min
reoxygenation
75 min
Stabilisation 
Group 3
Ischaemic preconditioning
Groups 4&5
High dose atorvastatin 
plus inhibitors
LY294002 
or UO126
or L-NAME
or 1400W
Or DMSO
 
Fig 5.1 – Experimental protocol for trabeculae  
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Results 
Baseline functional data 
At baseline, the contractile function of atrial myocardium was comparable 
between groups, with a mean contractile force of 0.85±0.08g in the control 
group, and 0.88±0.04g in the high dose atorvastatin intervention arms. 
Recovery of Function 
Following 90 minutes of hypoxia, followed by 120 minutes of reoxygenation, 
the control-group atrial trabeculae recovered 35.54±1.1% of their baseline 
contractile function.  Hypoxic preconditioning (using 3 minutes hypoxia and 7 
minutes reoxygenation prior to the main hypoxic insult) included as a positive 
control, improved recovery of contractile function to 55.66±2.7%.  In patients 
treated with high-dose preoperative atorvastatin, a similar improvement was 
seen, with trabeculae recovering 54.44±% of baseline function.   This was 
highly statistically significant (p<0.001) when compared with the control 
group. 
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Fig 5.2 – Recovery of contractile function in trabeculae exposed to high-dose 
atorvastatin compared alongside control group and positive control. 
 
This marked improvement in recovery of contractile function was not 
abolished by either the PI3-K inhibitor LY 294002, or by the Erk-1/2 inhibitor 
UO126.  However, the nonspecific NOS inhibitor, L-NAME, and the specific 
iNOS inhibitor 1400W did significantly abolish the improvement seen with 
high-dose preoperative atorvastatin.   
 
 
132 
 
 
Fig 5.3 – Recovery of contractile function with RISK pathway and NOS 
inhibitors 
 
Diabetic subgroup 
A direct comparison between diabetic patients receiving high-dose 
atorvastatin pre-treatment against non-diabetic patients in the same control 
was performed.  Mean recovery of function in diabetic patients receiving 
high-dose atorvastatin (n=9 trabeculae) was 55.07±2.99%.  In the non-
diabetic group receiving high-dose atorvastatin (n=14) trabeculae recovered 
54.36%±1.89 of baseline function.  By comparison, recovery in the diabetic 
control group was 35.14±2.1%.  Interestingly, recovery of function was 
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effectively the same in both diabetic and no-diabetic control patients 
undergoing hypoxic preconditioning – 55.34±5.8% vs. 55.79±3.2% 
respectively. 
 
 
Figure 5.4 - Functional recovery of diabetic control trabeculae exposed only 
to chronic statins (Control-DM), high-dose preoperative atorvastatin 
trabeculae from diabetic patients (HDATV-DM) and high-dose preoperative 
atorvastatin trabeculae from non-diabetic patients (HDATV-Non DM) 
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Discussion 
 
The major findings in this study are: (a) cardioprotection against simulated 
ischaemia-reperfusion injury of human atrial myocardium exposed to chronic 
statin therapy can be recaptured by treatment with high-dose atorvastatin 
and (b) the protection offered by this approach is abolished by inhibitors of 
NOS, but not by inhibitors of PI3K or Erk-1/2.  This confirms the pivotal role 
of NOS in the mediation of atorvastatin-induced cardioprotection in humans 
in this setting. 
Statin-induced cardioprotection 
 
The ability of statins to protect against ischaemia-reperfusion injury has been 
established in isolated perfused hearts (72;180;284;306;307), in-vivo animal 
models (103;104;109;291;292) and in isolated human ventricular 
cardiomyocytes (323), with protection deriving from activation of the RISK 
pathway and NOS signalling systems  (72;106;291).   
NOS is a key component of the cardioprotective cascade 
 
NO, produced by NOS isoforms, is a key regulator of vascular and 
myocardial function (324;325).  eNOS derived NO has been shown to be 
markedly reduced after experimental myocardial infarction and in the setting 
of heart failure (326;327).  
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Experimental infarct size reduction is seen with the both the administration of 
NO precursors, and with direct eNOS enhancers, confirming its 
cardioprotective effect (328;329).   
 
Statins enhance eNOS activity and expression 
 
Enhanced eNOS expression and activity is central to statin-induced 
cardioprotection.  Furthermore, statin cardioprotection cannot be elicited in 
the absence of eNOS, as evidenced by a lack of protective effect in eNOS-
deficient animal models (72;312)  Studies suggest that statin-induced 
cardioprotection is mediated by a direct increase in eNOS protein 
expression, as a result of a stabilising effect upon eNOS mRNA (309-311).  
Also, eNOS expression is increased with statin therapy, due to blocking of 
geranylgeranylation of the eNOS down-regulator, small GTPase Rho 
(254;311). Additionally, the protective effect of statins may be mediated by 
increased eNOS phosphorylation at the serine-1177 site, rather than an 
absolute increase in its absolute concentration.  This phosphorylation is 
thought to be induced by the PI3K-Akt cascade (313).  Specifically, 
atorvastatin has been demonstrated to act in this way in isolated mouse 
hearts exposed to ischaemia (72).  If this is the upstream trigger, it is 
possible that the RISK cascade has already had an effect in this 
experimental setting, following oral administration of the drug, and the 
subsequent inhibition of RISK enzymes alone was too late to abrogate 
cardioprotection.  In this experimental model, it seems likely that the RISK 
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cascade had already stabilised and enhanced eNOS activity in the hours 
following ingestion of the drug. 
 
Why did RISK pathway inhibition fail to abrogate protection? 
 
Activation of the RISK pathway is a key determinant of the acute 
cardioprotective effect of statins.  However, in this experimental setting, the 
inhibition of PI3K and Erk-1/2 did not abolish cardioprotection, which would 
be expected if the RISK pathway was the sole or main mechanism in 
operation. 
Whilst the RISK cascade is the main process involved in acute 
cardioprotection, the results here could be due to delayed form of 
preconditioning, or pharmacological preconditioning.  In these forms of 
cardioprotection, RISK activation may be a key trigger, but with a diminished 
role later on. This will be discussed further below. The RISK pathway is 
certainly implicated in statin-induced cardioprotection (see Chapter 4), but in 
a way which relies on NOS isoforms as downstream effectors.  It is possible 
that the RISK pathway had already exerted any effect it may have, and that 
its inhibition at the point of reoxygenation was simply too late to reverse the 
function of activated protective cascades downstream. 
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Is this a form of delayed preconditioning? 
 
Delayed, or second-window preconditioning results in cardioprotection 24 
hours after the conditioning stimulus, with a duration of 2-3 days (330). 
Atorvastatin has been shown to induce both acute and delayed myocardial 
preconditioning effects in vivo, with delayed preconditioning particularly 
mediated by iNOS (331). Both the presence and activity of eNOS and iNOS 
have been shown to be crucial in animal studies, with inhibition of either or 
both abrogating cardioprotection (72;103;105;107;291).  Several studies 
confirm the key role of iNOS in delayed type (332-334)  and pharmacological 
preconditioning (335-339).  iNOS, when expressed in cardiomyocytes, is a 
profoundly protective protein (340).   This is supported in this model by the 
finding that 1400w, a specific iNOS inhibitor, abolished cardioprotection.  If 
the atorvastatin is inducing a delayed type of preconditioning, it could be 
argued that there exists a biphasic role of NOS isoforms, with eNOS acting 
as a trigger for initiating the protective cascade, and iNOS functioning as an 
essential mediator (339).  In the delayed type cardioprotection, eNOS 
derived NO initiates a cascade of molecular events that results in the 
delayed activation of iNOS, which then confers protection (341).  However, 
the ability of L-NAME, a nonspecific (and by inference eNOS) NOS inhibitor 
to abolish protection suggests that eNOS still has a role in this setting.  It is 
likely that both eNOS and iNOS are both required to elicit delayed 
pharmacological cardioprotection (342) 
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Atorvastatin-induced NO interacts with mitochondria 
As described previously, opening of the mitochondrial permeability transition 
pore during early reperfusion is a critical determinant of ischaemia-
reperfusion injury (56;278;343).  Enhanced bioavailability of NO may inhibit 
pore opening, and studies using NO donor agents confirm this link, as they 
offer cardioprotection due to their ability to protect with inhibition of the pore 
(344;345). Putative mechanisms suggested include interaction with the 
mitochondrial electron transport chain, and attenuation of mitochondrial 
depolarisation  (346).  Binding with the oxygen binding centre of cytochrome 
oxidase, NO effectively limits mitochondrial activity during an ischaemic 
insult.  In turn, this could prevent generation of reactive oxygen species, 
reduce calcium uptake and inhibit formation of the pore (347;348).  This  
interaction with components of the electron transport chain limits post-
ischaemic damage, and provides a fundamental molecular explanation for 
the mechanism of NO-mediated cardioprotection (340). 
Diabetic subgroup 
 
Diabetic patients are at particular risk of cardiovascular disease (294;295) . 
Studies suggest that conventional preconditioning techniques fail in the 
setting of diabetes (229;297-299).  Animal studies, and studies using human 
myocardium have confirmed that  a higher intensity preconditioning stimulus 
must be applied  when compared to non-diabetics (301), possibly due to 
impaired PI3K/Akt signalling (302-305). It appears that in the setting of 
diabetes, the threshold for cardioprotection is raised.  These experimental 
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data confirm that the cardioprotective effect seen with atorvastatin extends to 
include the high-risk diabetic population.   
 
Clinical applicability 
 
Both CABG surgery and PCI have been shown to be associated with 
myocardial injury as an unwanted side effect of the therapeutic intervention,  
evidenced by biomarker release and magnetic resonance imaging data 
(122;268), and in both settings are associated with adverse clinical 
outcomes.  Clinical studies have demonstrated that statins (102;315;316), 
and in particular high-dose atorvastatin, can reduce periprocedural event 
rates (100;101;190), and these experimental findings outlined above could 
provide an explanation of the underpinning mechanism of these clinical 
effects.   
 
Conclusion 
This study demonstrates for the first time that high-dose oral atorvastatin 
pre-treatment of patients undergoing cardiac surgery, taking chronic statin 
therapy, protects the human atrial myocardium ex vivo against simulated 
ischaemia-reperfusion injury.  This protection is mediated by NOS.  The 
ability of oral atorvastatin to induce a pharmacologically preconditioned state 
provides a potential explanation for clinical studies demonstrating reduced 
periprocedural events, and provides a basis for strategies to reduce 
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periprocedural myocardial injury in the clinical setting of cardiac surgery or 
PCI. 
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Chapter Six: THE MITOCHONDRIAL PERMEABILITY 
TRANSITION PORE IS THE THERAPEUTIC TARGET 
FOR ATORVASTATIN AND CICLOSPORIN IN THE 
PROTECTION OF HUMAN VENTRICULAR 
CARDIOMYOCYTES ISOLATED FROM PATIENTS 
WITH HYPERTROPHIC CARDIOMYOPATHY 
 
Introduction 
In addition to the histological picture of ventricular hypertrophy and myocyte 
abnormalities outlined in the introductory chapter above, the 
pathophysiological features of hypertrophic cardiomyopathy lead to a milieu 
of ongoing oxidative stress (212) and chronic regional myocardial ischaemia  
(225;349).  Increased myocardial mass leads, in turn, to an increase in basal 
myocardial oxygen requirements.  In addition, the intramural coronary 
vessels are of relatively small calibre due to medial hypertrophy (217;218).   
The extravascular compressive forces applied by the bulky myocardium can 
further exacerbate myocardial perfusion, and can compromise flow in large 
septal and epicardial vessels.  At the myocyte level, disarray leads to 
inefficient contraction, leading to further circulatory demands.  These multiple 
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factors combine to result in reduced coronary flow reserve (219-224), and a 
myocardium which is frequently exposed to ischaemia, resulting in myocyte 
necrosis and replacement of the normal architecture with fibrotic tissue.  
HCM affected hearts are highly sensitive to the adverse effects of ischaemia 
(227;228).  The combined effect of myocardial metabolic defects, an ongoing 
chronic inflammatory response and activation of adverse neuro-humoral 
pathways render the HCM myocardium more prone to injury than in 
unaffected subjects (230-232).  Energy substrate use and calcium handling 
is impaired, and these factors further compromise post-ischaemic myocyte 
recovery (230;232;233;233;235). 
 
To avoid sudden cardiac death from arrhythmia, risk stratification is 
performed to identify high-risk individuals who would benefit from an 
implantable cardioverter-defibrillator.  Drug therapy using negatively inotropic 
antiarrhythmic drugs is employed to control symptoms, but has no disease 
modifying effect (206).  Additionally, alcohol septal ablation can be 
performed percutaneously and will aid with breathlessness or syncope in 
carefully selected cases.  In refractory cases, surgical excision of excess 
bulky septal tissue can be performed with good results  (206).  However, 
despite recent advances in cardiovascular medicine, no pharmacological 
therapies currently exist which modify or inhibit disease progression, and all 
hopes are currently pinned on gene therapy becoming available with which 
to combat this common condition (247).  Similarly, protection of this highly 
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susceptible myocardium from ischaemia-reperfusion injury during cardiac 
surgery (e.g. during myectomy, valve surgery or concomitant bypass 
grafting) or during percutaneous coronary intervention has not been 
addressed or studied to date.   
Coronary artery disease often co-exists with HCM from mid-life onwards 
(236-240).  Long term follow-up data shows that the co-existence of these 
two disease processes carries a very adverse prognosis, with a very poor 
10-year survival rate (242).  The ability of conventional cardioprotective 
measures targeting prosurvival signalling pathways to help save myocardium 
at risk in this very high risk cohort of patients has not been investigated, but 
these therapies could have the potential to protect this cohort of very high 
risk patients. As an example, in a study of non-HCM human right ventricular 
cardiomyocytes, statin therapy was shown to induce resistance against 
hypoxia-reoxygenation injury, possibly acting via enhanced levels of nitric 
oxide synthase (323). 
The ability of pharmacological agents to activate prosurvival signalling 
pathways in HCM, which might then act to inhibit adverse mitochondrial 
changes, would potentially confer powerful cardioprotective effects 
(65;280;350). 
 
Hypothesis 
Human ventricular myocardium from clinical subjects with hypertrophic 
cardiomyopathy can be pharmacologically cardioprotected. 
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Objectives 
The objectives of this study were; 
 
1.  To establish whether inhibition of mPTP opening in response to oxidative 
stress in HCM could be achieved in isolated human ventricular 
cardiomyocytes using ciclosporin A, an agent known to inhibit pore opening 
in non-HCM human cardiac cells (64), and; 
 
2.  To establish if inhibition of mPTP opening in response to oxidative stress 
in HCM could be achieved in isolated human ventricular cardiomyocytes 
using atorvastatin, an HMG Co-A reductase inhibitor known to protect from 
ischaemia-reperfusion injury by activation of the prosurvival signalling 
pathways (72). 
 
Materials and methods 
Atorvastatin was supplied by Pfizer Incorporated, USA.  It was dissolved in 
dimethyl sulphoxide (DMSO).  The final concentration of DMSO was 
<0.01%.  Ciclosporin A was supplied by Merck Chemicals, UK.  It was also 
dissolved in DMSO, with a final concentration of <0.01%.  The experimental 
methods have been detailed in chapter 3. 
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Experimental protocol 
Loaded coverslip wells containing freshly isolated human ventricular 
cardiomyocytes isolated from HCM patients undergoing surgical myectomy 
were randomised into control and drug-intervention groups, using a 
standardised isolation protocol (275).   All wells were loaded with TMRM 
3µM and allowed to incubate for 5 minutes at room temperature prior to 
confocal microscopy.  In the drug-intervention arms, the agents were added 
via micropipette 5 minutes after the addition of the TMRM, and incubated for 
a further 10 minutes.  In control groups, DMSO alone was instilled at this 
point and further 10 minutes incubation permitted.  Total TMRM incubation 
time was limited to 15 minutes in all groups, to avoid preferential loading of 
any cell groups which could have resulted in potentially enhanced 
susceptibility to laser stress.  In groups randomised to receive ciclosporin A, 
a final concentration of 0.2 µM in the buffer was administered.  In the 
atorvastatin group, the concentration investigated was 25 µM.  The 
concentrations were selected based on previously published data confirming 
cardioprotective efficacy at these doses in a variety of models including 
isolated cells (64;72;278;279). 
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Study Subjects 
 
8 patients undergoing surgical myectomy for obstructive HCM consented to 
this study and underwent tissue harvest, myocyte isolation and experimental 
studies: 
 
Total patients in study 8 
Male 5 
Female 3 
Age range 28-55 
Mean age 47 
 
Table 6.1 – Study subjects undergoing septal myectomy consenting to 
myocyte isolation 
 
 
Results 
From 8 patients, a total of 20 groups of cells underwent analysis in a 
randomised fashion as described above.  A control group was included in 
each experiment.  In the control group, mPTP opening was induced after 
188.7 ±22.7 seconds of oxidative stress, providing evidence for a functional 
mPTP in the setting of HCM.  Pre-treatment with the known mPTP inhibitor, 
CsA, delayed the onset of mPTP opening by 51±10% (P<0.001) to 
284.94±18.81 seconds.  Treatment with atorvastatin delayed the onset of 
mPTP opening by 35±7% (P<0.05), to 252.48±11.32 seconds. 
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Fig 6.1 – Comparison of time to mPTP opening in groups of cells 
Discussion 
The main findings from this study are (a) that mPTP opening in isolated 
human ventricular cardiomyocytes with HCM is a critical determinant of cell 
death.  This was evidenced here by the application of a standardised laser 
insult to induce mitochondrial oxidative stress, leading to pore opening with 
subsequent loss of mitochondrial membrane potential.  This was detected by 
observing for an increase in cytosol TMRM fluorescence intensity, following 
loss of the dye from the mitochondria once the membrane had been 
breached;  (b) inhibition of mPTP opening in response to oxidative stress in 
HCM can be achieved in isolated human ventricular cardiomyocytes using 
ciclosporin A; and (c) inhibition of mPTP opening in response to oxidative 
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stress in HCM could be achieved in isolated human ventricular 
cardiomyocytes using atorvastatin, an HMG Co-A reductase inhibitor known 
to protect from ischaemia-reperfusion injury by activation of  prosurvival 
signalling pathways (72). 
This is the first time in humans that the ability of HCM cardiomyocytes to 
derive benefit from cardioprotective mechanisms active in non-HCM settings 
has been established.   
 
How could these findings be of potential clinical benefit? 
 
The particular importance of ongoing ischaemia within the myocardium in the 
setting of HCM was first confirmed from an Italian post-mortem study which 
identified areas of myocardial damage within the hearts of patients who had 
suffered sudden death (351).  Autopsy studies then went on to demonstrate 
structural abnormalities of intramural coronary vasculature, including 
thickening of the intima and medial layers of the blood vessels (218;221).  
These features can lead to an impaired vasodilatory capacity and thereby 
blunt myocardial blood flow during stress, leading to hypoperfusion and 
ischaemia (220;352;353).  Evidence for ongoing subclinical myocardial  
ischaemia is supported by a clinical study which found abnormal levels of 
circulating serum cardiac troponins in 50% of HCM subjects, with a trend to 
more severe disease characteristics in that group (354).  Observations from 
nuclear imaging and cardiac magnetic resonance imaging studies confirm 
impaired hyperaemic blood flow and an association between chronic 
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ischaemia and myocardial fibrosis (355-357) .  It is likely that the abnormal 
myocardial perfusion caused by microvascular dysfunction leads to 
myocardial ischaemia-related myocyte death and subsequent replacement 
by fibrotic tissue (225).  A therapy which could modulate myocyte resistance 
to ongoing episodes of ischaemia could interrupt this process and preserve 
myocyte viability.   
 
A key role for either of these agents could include a reduction in 
cardiomyocyte death due to episodes of ischaemia-reperfusion injury, 
leading to a reduction in replacement with fibrotic tissue.   The evidence 
currently would suggest that reduction of ischaemic damage could improve 
the clinical picture.  Data from MRI studies suggest strongly that the degree 
of fibrosis in HCM positively correlates with the degree of left ventricular 
impairment, and progression to adverse clinical outcomes such as the 
development of atrial fibrillation, life-threatening arrhythmias and progression 
to overt heart failure, as might be expected (358-361). 
 
What role might ciclosporin have, and what evidence is there that 
it is useful?  
 
Its role in ameliorating ischaemia-reperfusion injury by inhibition of the mPTP 
is well established in cellular (63;65;278;280;343) and ex-vivo models 
(362;363).  In humans, cyclosporine has been shown to protect via delaying 
mPTP opening  in a laser model of cardiomyocyte oxidative stress (64), and 
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in an ex-vivo atrial trabecular model of simulated ischaemia-reperfusion 
(364).  Additionally, clinical MRI data confirms that, used an adjunct to 
emergency percutaneous coronary intervention for acute myocardial 
infarction, cyclosporine reduces final infarct mass (365).  These findings are 
present acutely at day 5 post-infarction, and persist through longer-term 
follow up at 6 months (366), and lend support to the notion that the agent 
has a role in modifying the effects of myocardial ischaemia-reperfusion 
injury. 
 
Are there any other potential benefits of the drug? 
 
Calcineurin, a calcium-regulated phosphatase, plays a critical role in the 
pathogenesis of HCM. Administration of  cyclosporine, which is a known 
inhibitor of calcineurin, has been shown to prevent disease in mice that were 
genetically predisposed to develop HCM as a result of aberrant expression 
of tropomodulin, myosin Light chain-2, or fetal beta-tropomyosin proteins 
(367). Ciclosporin had a similar effect in a rat model of pressure-overload 
hypertrophy, so could theoretically have an anti-hypertrophy role in HCM 
(368).  However, on a cautionary note, some investigators have shown that 
in a mouse form of HCM, ciclosporin A treatment actually augmented 
hypertrophy, possibly due to a shared hypertrophic signalling pathway which, 
paradoxically, triggered myocyte growth.(369;370)  So whilst cyclosporine 
may offer a protective effect from reduction of myocyte damage during 
periods of ischaemia, the long term safety in terms of anti or pro-hypertrophy 
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effects are unknown.  In addition, cyclosporine is an immunomodulatory and 
immunosuppressive drug, which requires ongoing therapeutic level 
monitoring, and carries with it a risk of infection.  These factors mean that it 
is probably not a practical long-term therapy solution for the majority of HCM 
patients; at least not until any disease modification effect is well established. 
 
Is atorvastatin therapy a viable alternative?   
 
The role of statins in primary and secondary prevention of coronary artery 
disease is well established, and discussed elsewhere.  What we do know 
about atorvastatin is that it is the most widely used HMG-CoA reductase 
inhibitor, and that it is safe and well tolerated, even at the intensive therapy 
dose of 80mg daily (115). One key role for atorvastatin in HCM could lie with 
the modification of the myocyte response to episodes of ischaemia-
reperfusion injury.  Atorvastatin is well established as an agent that can 
cardioprotect via activation of the prosurvival RISK pathway (72).  In a rat 
cardiomyocyte model identical to that used above, activation of the PI(3)K-
Akt prosurvival kinase pathway inhibited opening of the mPTP, and 
confirmed the important link between the survival kinases and the pore (65).  
This could explain the differential prolongation in cell survival times seen in 
this study, with cyclosporine perhaps acting more immediately and directly at 
pore level and resulting in more established pore inhibition, whilst 
atorvastatin confers its protection acting via a signalling pathway.   This 
could be the reason behind it being relatively less protective (than 
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cyclosporine) in this study, when the stress stimulus was applied within a 
matter of minutes following drug exposure. 
Pharmacological inhibition of components of the RISK pathway, to better 
delineate the signalling pathways involved,  has been previously described in 
this cellular model (65). Repeating these experiments with further cell 
groups, including groups in the presence of the inhibitors would allow further 
elucidation of the signalling pathways involved.   
 
Is atorvastatin inducing NO-mediated inhibition of the mPTP? 
 
Enhanced eNOS expression is a key component of statin-induced 
cardioprotection, and statin cardioprotection cannot be elicited in eNOS 
deficient models (72;312)  Statin-induced cardioprotection is mediated by 
eNOS mRNA stabilisation (309-311), through the blocking of 
geranylgeranylation of small GTPases in the heart  (254;311),  and 
additionally may be mediated by increased eNOS phosphorylation, induced 
by the PI3K-Akt cascade (72;313).    
Both presence and activity of eNOS and iNOS have been shown to be 
crucial in animal studies, with inhibition of either or both abrogating 
cardioprotection.  At the cellular level, experimental studies in  rat myocyte 
models showed that  pretreatment with an NO donor induces a modest, 
sustained mitochondrial depolarization and protects cardiomyocytes from 
ischaemia-reperfusion injury ,  with a concomitant reduction in cytosol and 
mitochondrial calcium levels.   Binding with cytochrome oxidase, NO 
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interacts with the mitochondrial electron transport chain and limits 
mitochondrial activity during the ischaemic insult by causing slight 
mitochondrial depolarisation  (340;347;348).  Enhanced bioavailability of NO, 
secondary to enhanced eNOS and iNOS activity induced by atorvastatin, 
may thus inhibit pore opening, and this mechanism could be operating in this 
model (344;345). 
 
Are there any other proven benefits to atorvastatin used in the 
setting of HCM? 
 
Both simvastatin and atorvastatin have been shown to prevent, reduce and 
reverse cardiac hypertrophy and fibrosis in transgenic animal models of 
HCM, with a concomitant reduction in the levels of cardiac fibrosis (263;264)  
Clinical studies in humans have demonstrated that statin therapy leads to 
reduction in left ventricular mass in HCM patients with angina, hinting that it 
may be of benefit in this high-risk cohort of patients (261).  Other pilot 
studies of statin use in HCM patients have been inconclusive or unhelpful, 
mostly due to study design, drug dose or patient compliance issues 
(371;372).  The investigators have also probably looked for the wrong end-
points, using crude echocardiographic markers of LV mass rather than more 
contemporaneous detailed MRI assessments of mass and function, coupled 
with stress perfusion data to delineate and quantify ischaemic burden 
(225;265).   However, atorvastatin probably does have additional positive 
structural effects on the myocardium, as evidenced by improved extracellular 
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remodelling indices in patients with high-risk coronary disease (373) , in 
addition to a potential anti-hypertrophy role.  These potential avenues need 
to be investigated by further detailed MRI fibrosis and stress perfusion 
studies.   
 
Cardioprotection during acute coronary syndromes in HCM 
patients 
 
As outlined above, HCM and coronary disease frequently occur together, 
and confer a particularly adverse prognosis (241;242) .  Evidence that the 
pharmacological cardioprotection pathways being investigated in “normal” 
subjects also exist in the setting of HCM is favourable in that HCM subjects 
with acute coronary syndromes could potentially benefit from interventions 
proven in non-HCM settings.  In this study, the role of the mPTP, central to 
the control of myocyte death (56), has been established in the setting of 
HCM ,and the potential of drug therapy to modify and reduce myocyte injury 
through its inhibition has been demonstrated.  As with all cardioprotective 
interventions, pharmacological and non-pharmacological, the challenge of 
translating these into findings into clinical practice remains huge (27;374).   
 
Periprocedural intervention 
 
Perioperative cardioprotection has been discussed elsewhere, but another 
potential exploitation of this cardioprotective mechanism might be in the 
setting of HCM patients undergoing procedures where myocardial damage 
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could be predicted. Specifically this would include the settings of cardiac 
surgery or percutaneous coronary intervention for coronary artery disease.  
Around 5% of patients with HCM will require surgical intervention by means 
of surgical myectomy, for severe left ventricular outflow tract disease (202).  
The application of a cardioprotective agents to reduce myocardial ischaemia-
reperfusion injury associated with the mechanical effects of surgical handling 
during myectomy, and from the cardiopulmonary bypass insult would be a 
potential therapeutic avenue, and current studies of pharmacological 
intervention with statins in  cardiac surgery appear promising, especially in 
reducing early postoperative adverse outcomes (138;164-
166;170;171;174;177). 
 
Limitations  
 
One potential criticism of this data would include the issue of genetic 
heterogeneity of the sample. No genetic subtypes had been identified 
amongst the study patients, and it is clearly possible that, in some genetic 
HCM subtypes, the outlined cardioprotective mechanisms may be impaired 
or absent due to the underlying genetic lesion.  However, it is not current 
practice to perform detailed genetic analysis on these patients, and study 
design mandating this would yield data that is not necessarily applicable in 
normal clinical practice.  Indeed, data which applies to “all comers” is 
potentially more clinically valuable in a condition with significant and 
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expanding heterogeneity (197), currently running at 1000 mutations in 13 or 
more genes (196;198;199). 
Additionally, it is accepted that the numbers of cell groups are relatively 
small, although cell yields did steadily improve with continued repeated 
operator exposure to the isolation process.  During the course of the study, 
preparations were made to move the isolation process closer to the point of 
surgery, to further assist with gaining higher-yield isolations.  However, the 
main strength of this data is that it has been gained through the use of 
human cells, isolated from live patients. 
 
Conclusion 
 
The present study demonstrates, for the first time in an isolated human 
ventricular myocyte model, that the mPTP is functional in the setting of 
human HCM.  Additionally, its opening can be delayed by ciclosporin and 
atorvastatin, both agents know to have a cardioprotective effect in non-HCM 
settings.  The ability to modify cardiomyocyte response to ischaemia-
reperfusion injury could play a role not only in acute cardioprotection during 
acute coronary syndromes or during surgical/percutaneous interventions, but 
also in long-term disease modification in HCM, where the presence of 
impaired coronary reserve and hypoperfusion is well proven.  Ultimately, 
such a therapy could reduce the progression of cell death and myocardial 
fibrosis, shown to be associated with an adverse long-term clinical outcome.
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Chapter Seven: DISCUSSION 
 
An overview of the findings 
This thesis has described three experimental investigations aimed at 
elucidating cardioprotective mechanisms in the human myocardium.  The 
experimental protocols have examined pharmacological cardioprotection in 
the setting of “normal”, diabetic and HCM-affected hearts.  Each 
investigative avenue has sought to confirm the applicability of the existing 
animal data to the setting of human cardioprotection.  The main investigative 
effort has been to establish whether pharmacological activation of the 
Reperfusion Injury Salvage Kinase (RISK) enzymes and nitric oxide 
synthase isoforms is possible using Atorvastatin, and whether this confers 
cardioprotection against ischaemia-reperfusion injury.  Studies also 
examined the effects of Atorvastatin with regards to mitochondrial 
permeability transition pore inhibition in the setting of hearts affected by 
hypertrophic cardiomyopathy, which are even more vulnerable to the effects 
of ischaemia than “normal” hearts, and chronically affected by repeated 
episodes of ischaemia-reperfusion injury. 
Chapter four described experiments relating to acute cardioprotection of 
human atrial myocardium using Atorvastatin administered at the point of 
reoxygenation, following a period of ex-vivo hypoxia-reoxygenation injury.  
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For the first time in human myocardium, it was demonstrated that 
Atorvastatin can protect human atrial myocardium as evidenced by a marked 
improvement in recovery of contractile function.  This cardioprotective effect 
was similar in magnitude to that afforded in previous studies of human 
myocardium by ischaemic preconditioning techniques (270), administration 
of pharmacological agents (83),  and ischaemic postconditioning (82) .  All 
these techniques have a shared pharmacological basis in that they have all 
been shown to activate the RISK pathway (287), in which key elements are 
the activation of the PI3-kinase and Erk-1/2 protein kinases (286).  By using 
specific inhibitor agents it has now been shown that this pathway is 
mechanistically important in the acute cardioprotection seen with 
Atorvastatin in humans.  Specifically, inhibition of PI3-kinase by the inhibitor 
agent LY294002 abrogated protection, as did inhibition of Erk-1/2 kinase by 
UO126.  Statin-induced cardioprotection has also been associated with 
activation of nitric oxide synthase (NOS) isoforms, and this was also 
investigated in the studies presented in this thesis.  Statins have been shown 
to stabilise eNOS mRNA (309-311), and phosphorylation of eNOS directly by 
the PI3K and Akt signalling cascades may increase cardioprotective eNOS 
activity (313).  In this experimental setting, the addition of L-NAME at re-
oxygenation, a non-specific NOS inhibitor abrogated protection, as did the 
iNOS-specific inhibitor 1400W.  Despite previous studies suggesting a higher 
threshold for achieving protection in diabetic patients (304), data from a 
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small diabetic subgroup suggests that this cardioprotective effect is also 
applicable even with underlying diabetes. 
From the host of animal data available, the most consistent finding using 
Atorvastatin in this setting is activation of the RISK pathway and NOS 
signalling systems (72;106;291) and these new findings confirm the key role 
of both the RISK pathway and NOS in the mediation of Atorvastatin-induced 
acute cardioprotection in humans.   
 
Chapter five focused on assessing whether an acute dose of Atorvastatin 
can re-capture cardioprotection, where chronic background statin therapy 
has been administered.  Previous animal studies have shown that the 
cardioprotective effects of statins reduce after acute administration, due to 
activity of a house-keeping phosphatase, PTEN (189) .  PTEN effectively 
reduces the phosphorylation states of the RISK enzymes back to their 
baseline state to avoid chronic cell dysfunction and hypertrophy (375).  This 
loss of cardioprotection can be averted, in animal models, by giving an 
additional high dose of statin prior to experimental myocardial infarction 
(180)   Recent clinical studies have shown that an additional “top-up” dose of 
Atorvastatin can be used to reduce periprocedural myocardial injury 
following percutaneous coronary intervention as evidence by reduced 
biomarker release (123;190), and this study sought to suggest a potential 
mechanism to explain this and similar findings.  In this study, administration 
of a 160mg dose of Atorvastatin 12 hours prior to hypoxia-reoxygenation 
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injury recaptured cardioprotection in ex-vivo human atrial myocardium 
explanted from patients undergoing cardiac surgery, as evidenced by a 
significant improvement in recovery of contractile function.  Again, the 
potential roles of RISK pathway enzymes and NOS isoforms were assessed 
using inhibitor agents.  Interestingly, neither inhibition of PI3-kinase by 
LY294002 nor inhibition of Erk-1/2 MAP kinase by UO126 abrogated 
cardioprotection here.  It is possible that the RISK cascade had already had 
its effect by the time of simulated reperfusion in this experimental setting, 
having been administered some 12 hours prior.  Perhaps the inhibition at the 
point of simulated reperfusion was simply too late.  However, both the NOS 
inhibitors (L-NAME and 1400w) abrogated protection.  It is suggested that 
Atorvastatin can induce a form of pharmacological preconditioning (delayed, 
or second-window cardioprotection) in which iNOS is a particularly important 
mediator (332-338), and previous workers have elucidated that eNOS has 
an early role in activating a protective cascade, with iNOS being the effector 
later on (341). However, these experimental findings support the contention 
that  both NOS isoforms are active in eliciting delayed cardioprotection, and 
that they are both important during the reperfusion phase (342).   
 
Chapter 6 described an investigation into possible cardioprotective 
mechanisms in the setting of hypertrophic cardiomyopathy (HCM).  HCM is 
the most common inherited cardiovascular disorder, affecting up to 1 in 500 
people (195-197), caused by mutation-induced dysfunction of the 
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sarcomere.  We have demonstrated for the first time that the opening of the 
mitochondrial permeability transition pore (mPTP), a critical determinant of 
reperfusion injury (56;376), occurs in the setting of HCM.  This work was 
performed on human cardiomyocytes harvested from patients undergoing 
cardiac surgery to relieve left ventricular outflow tract obstruction, and used a 
standardised laser insult to induce oxidative stress within the cells.  
Importantly, inhibition of the mPTP was possible using ciclosporin A as a 
positive control, an agent known to inhibit pore opening in animal models 
and non-HCM human atrial tissue (64;280;362).  Additionally, Atorvastatin 
was also able to delay mPTP opening when administered to HCM-affected 
cells prior immediately prior to oxidative stress, which may be due to a direct 
effect on the mPTP, or as a result of activation of prosurvival signalling 
pathways.  Moreover, the study has confirmed that the mPTP is a potential 
therapeutic target for cardioprotection in the setting of HCM, and the 
implications of this will be discussed further below. 
 
Clinical implications 
A common uniting theme in all these investigations is the ability of 
Atorvastatin to induce cardioprotection in human myocardium in a variety of 
settings, via subtly differing pathways.  The ability of Atorvastatin to 
cardioprotect acutely seems to be due to activation of the RISK pathway, in 
particular PI3-kinase, Erk-1/2, and this is in keeping with the wealth of 
experimental animal data (72;285).  Additionally, the roles of both eNOS and 
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iNOS are strongly implicated in acute Atorvastatin-induced cardioprotection, 
possibly as effectors, and this is also in keeping with previously published 
animal data (72;311).  Atorvastatin is in wide clinical use, is safe and well-
tolerated (115).  When given at high dose, it rapidly reaches 
pharmacologically active serum levels (116), and due to its lipophilic nature 
enters endothelial and other cells rapidly (179).  It would be an ideal 
pharmacological agent to study more closely following administration to 
patients suffering from ST-elevation myocardial infarction, and could be 
given in the prehospital setting (at home or in the ambulance). Even where 
direct transfer to a heart attack centre is undertaken, there is still a delay 
prior to mechanical reperfusion being established.  By administering en-route 
to hospital, the drug would have reached a pharmacologically active serum 
level, and thus be present in the circulation and be able to activate the RISK 
pathway once forward flow in the infarct related artery has been achieved by 
the interventional cardiologist performing primary PCI.  The ultimate aim of 
this pharmacological adjunctive therapy would be improved myocardial 
salvage and a reduction in final infarct size, translating into better long-term 
outcomes.  A unique contribution to this field is confirmation of the ability of 
Atorvastatin to cardioprotect via activation of the RISK pathway.  This could 
explain the underlying pharmacological mechanism responsible for  the 
positive findings of the clinical studies of Atorvastatin use in reducing 
periprocedural myocardial injury in the settings of both PCI (102;123) and 
cardiac surgery (174).   
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The ability of high-dose Atorvastatin administration to recapture 
cardioprotection in the setting of chronic background statin therapy extends 
the potential clinical benefits further.  Whether being used as an adjunct to 
reperfusion by primary PCI, or as an upstream therapy to protect patients 
undergoing elective revascularisation procedures, these studies have 
established that the down-regulating effects of PTEN can be overcome in 
human myocardium by a high-dose of Atorvastatin.  Given that current 
international guidelines recommend the use of chronic statin therapy as a 
secondary prevention measure in all patients with coronary artery disease, 
the majority of patients undergoing PCI or CABG should already be taking a 
statin.  High-dose Atorvastatin reloading may be a means by which we are 
able to offer a simple, safe drug intervention to recapture protection from 
periprocedural injury, and reduce adverse event rates.  The findings in 
chapter 5 may contribute a scientific basis for the results of recent clinical 
trial of cardioprotection during PCI (190). 
The mechanisms by which HCM causes damage to the myocardium are 
multifactorial and complex, and recent insights including advanced imaging 
and coronary techniques highlight the role of chronic spells of ischaemia-
reperfusion injury within the diseased heart (224;225).  Additionally, there 
are currently no medical therapies which can be offered to HCM patients 
which actually modify the disease – treatments only alleviate symptoms.  
The potential for Atorvastatin to be used to cardioprotect acting via the 
mPTP could have clinical applications in the acute setting of myocardial 
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infarction, as HCM and coronary disease frequently co-exist (240;241;243).  
Additionally it could have a role in reduction of periprocedural events in HCM 
patients undergoing PCI, CABG, surgical myectomy and percutaneous 
septal ablation.  There is also some data that support an anti-hypertrophy 
effect of statin therapy, although clinical trials have proved inconclusive.  
However, demonstrating the functionality of the mPTP as a determinant of 
cell death, and the ability to inhibit it using Atorvastatin in the setting of HCM 
is a step forward in understanding the mechanisms of cardioprotection 
potentially available in this condition.   This therapeutic avenue could 
possibly be used to modify the heart‟s response to chronic ischaemia-
reperfusion injury in HCM, perhaps even reducing fibrosis long-term.  
 
Future directions 
 
A common problem in research in the field of cardioprotection has been a 
hasty switch from small laboratory studies to large, heterogeneous clinical 
trials, often with serious design flaws which reduce the likelihood of 
scientifically robust and clinically meaningful results (374;377).  Whilst 
testing a cardioprotective agent in human heart tissue is a crucial 
translational step between bench and bedside, further basic science 
investigations could be used to better delineate the optimum cardioprotective 
effect of Atorvastatin.  Initially, further experiments using the human atrial 
model could be used to establish dose-response data for Atorvastatin, as in 
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animal models a therapeutic ceiling was reached, and further increases in 
dosing above 50 µM/L did not confer any additional protection (72).  As high-
dose Atorvastatin in the animal models sometimes results in transient 
hypotension, it is important that supra-therapeutic doses are not given which 
may confer haemodynamic instability (and thus potentially worsen outcome 
in the setting of acute coronary syndrome) where no additional 
cardioprotective benefit is possible.  Other statin agents should also be 
assessed, as cardioprotection in humans may be a class effect, particularly 
using agents of a similar lipophilic nature to Atorvastatin. 
 
Confirming that these findings are applicable in human ventricular muscle, 
the key clinical target of cardioprotection, could be achieved by using an 
isolated ventricular cardiomyocyte model using excised right ventricular 
outflow tract tissue similar to that used by Verma et al to investigate 
Pravastatin (323).  Additionally, the mPTP work could usefully be repeated 
with these cells, and this would extend our understanding of the interaction 
of Atorvastatin and the mPTP outside the setting of HCM.  A natural 
progression of this work would also include using hypoxia rather than laser-
induced oxidative stress, which would allow an investigation into cell survival 
in this setting, and whether this can be optimised in cells exposed to 
Atorvastatin. 
To establish the role of Atorvastatin with respect to increased eNOS 
expression, Western blotting or standard calibrated reverse-transcripted 
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polymerase chain reaction (PCR) techniques could be used to assess eNOS 
mRNA expression.  Additionally, a direct measurement of NOS activity can 
be performed using commercially available radiochemistry equipment.  
Similar work has been performed in human right atrial appendages 
harvested during cardiac surgery to assess the effects of angiotensin-
converting enzyme inhibitors (378) and β-adrenoceptor agonists (379-381).  
Some preliminary work using snap-frozen right atrial appendage tissue was 
commenced in this field, but requires much technical optimisation before 
meaningful data can be reliably obtained. 
 
In the setting of HCM, it would be valuable to cross back over to 
investigations using atrial tissue, and use explanted atrial trabeculae to 
confirm improved functional recovery with Atorvastatin following hypoxia-
reoxygenation injury.  These patients require full cardiopulmonary bypass for 
their surgery, and thus could potentially consent for right atrial appendage 
harvest to allow these experiments to be undertaken.  Potential underlying 
prosurvival cascades could be further assessed using RISK pathway 
inhibitors alongside Atorvastatin in either atrial tissue at reoxygenation, or by 
adding them to the cellular isolates.  As discussed above, hypoxia studies 
could also be performed in the isolated cardiomyocytes to assess the impact 
of Atorvastatin on cell survival. 
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Only when full delineation of the cellular mechanisms and optimal target 
doses are established should a formal prospective clinical study be 
designed, with special care to target an appropriate clinical setting, with 
careful patient selection, coupled with a proper assessment of myocardial 
salvage and area at risk, probably best determined using advanced 
magnetic imaging techniques. 
 
Conclusion 
In summary, these experiments have investigated the role of Atorvastatin 
with respect to acute cardioprotection of the human heart.  The key unique 
contribution to this field has been to provide a crucial translational step 
between bench and bedside, furthering our understanding of how 
Atorvastatin provides a cardioprotective effect in human cardiac tissue.
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